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Abstract 
Acinetobacter baumannii is a globally important nosocomial pathogen associated with 
clinical infections that are difficult to treat due to broad antimicrobial resistance. A. baumannii 
epidemics are caused by a limited number of strains worldwide, belonging to the initially 
named European clones, but now regarded to as International clonal lineages (IC) I, II and III 
and a few additional lineages recently emerged as epidemic clones in some regions, such as 
the sequence types (ST)10, ST15, ST25, ST78 and ST79 according to Pasteur’s multilocus 
sequencing typing (MLST) scheme. 
The first chapter of the thesis analyzes the genomic epidemiology of 19 A. baumannii 
strains belonging to the emerging ST25 lineage. Seven genomes from the sequence type 
(ST)25 lineage were sequenced and compared to 12 ST25 genomes deposited in public 
databases. A recombination analysis identified multiple genomic regions that are 
homoplasious in the ST25 phylogeny, indicating active or historical recombination. Genes 
associated with antimicrobial resistance were differentially distributed between ST25 
genomes, which matched our laboratory-based antimicrobial susceptibility typing. 
Differences were also observed in biofilm formation between ST25 isolates, which were 
demonstrated to produce significantly more extensive biofilm than an isolate from the ST1 
clonal lineage. These results demonstrate that within A. baumannii , even a fairly recently 
derived monophyletic lineage can still exhibit significant genotypic and phenotypic diversity. 
These results have implications for associating outbreaks with sequence typing as well as 
understanding mechanisms behind the global propagation of successful A. baumannii 
lineages. 
According to their antimicrobial susceptibility profile, A. baumannii strains can be 
classified as multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug- 
resistant (PDR) if they are resistant to three or more, all but one or two, and all classes of 
potentially effective antimicrobial agents, respectively. MDR and XDR in A. baumannii is 
now an emerging issue worldwide. Strains responsible for epidemics are resistant to 
carbapenems and show intermediate resistance to tigecycline, but usually retain susceptibility 
to colistin. The second chapter of the thesis describes the molecular epidemiology of 194- 
single patient carbapenem resistant A. baumannii (CRAB) isolates collected 
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randomly during 2015 from 11 tertiary hospitals located throughout Greece. CRAB isolates 
were MDR or XDR, the most active antibiotics being trimethoprim/sulfamethoxazole (SXT) 
(34.6% of isolates susceptible), minocycline (71.6%), colistin (72.7%) and tigecycline 
(MIC50/90 values, 1/2mg/L). The blaOXA-23-like gene was identified in 188 isolates 
(96.9%), blaOXA-23-like together with blaOXA-58-like in 3 isolates (1.5%), blaOXA-58- 
like in 2 isolates (1.0%) and blaOXA-40-like in 1 isolate (0.5%). ISAba1 was found upstream 
of the blaOXA-23-like gene in all isolates. International clone (IC) 2 comprised 157 isolates 
(80.9%), IC1 comprised 36 isolates (18.6%) and ST78 comprised 1 isolate (0.5%). All IC2 
and IC1 isolates tested by MLST were ST2 and ST1, respectively. Seven PFGE types were 
detected. IC2 isolates were resistant to more antibiotics than IC1, except for SXT. This 
nationwide study showed that CRAB isolates in Greek hospitals currently produce almost 
uniformly the OXA-23 carbapenemase and belong mainly to IC2 and, to a lesser extent, IC1. 
Of particular concern, colistin susceptibility is recently severely reduced. 
The spread of extensively drug-resistant (XDR) gram-negative bacteria has boosted 
colistin use, with a resultant selection of colistin-resistant, often pandrug-resistant strains. 
Whether acquisition of further resistance mechanisms translates into a reduced virulence is 
the subject of active research. The third chapter of the thesis analyzes phenotypic and 
genotypic characteristics, molecular mechanisms of colistin resistance, and in vitro and in 
vivo fitness of sequential colistin-sensitive and colistin-resistant A. baumannii strains 
isolated from an immunocompromised patient who developed infection due to colistin- 
resistant A. baumannii while on long-term colistin therapy. Both colistin-sensitive and 
colistin-resistant strains were XDR and showed identical ST78 genotype. At variance with 
prior reports on colistin-resistant strains of A. baumannii, resistance to colistin due to P233S 
mutation in PmrB sensor kinase did not associate with any measurable reduction in strain 
fitness, growth characteristics, and virulence. 
In addition to extensively antimicrobial resistance, A. baumannii strains responsible 
for epidemics show elevated resistance to desiccation, high biofilm-forming capacity on 
abiotic surfaces and adherence to host epithelial cells, virulence-related features which might 
have favored the spread and persistence in the hospital environment. As in other 
microrganisms, the formation of biofilm in A. baumannii is a redundantly organized, 
multifactorial process involving multiple cellular components. A giant protein called BAP 
(biofilm-associated protein) plays a role in biofilm formation and adhesion to host cells in A. 
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baumannii. Most of the protein is made by arrays of 80–110 aa modules featuring 
immunoglobulin-like (Ig-like) motifs. The fourth chapter of the thesis analyzes the 
organization of BAP coding sequences in wholly sequenced strains as in a large set of whole 
genome shotguns (WGS) of both A. baumannii and other Acinetobacter species. In silico 
analyses showed that BAP was highly polymorphic, distinguishable in three main types for 
changes both in the repetitive and the COOH region. Two additional proteins, BLP1 and 
BLP2 (for BAP-like proteins), structurally related to BAP because similarly containing Ig- 
like domains were identified among Acinetobacter species. BLP1 is missing in the majority 
of type-3 BAP strains. BLP2 was largely conserved, but was frequently missing in BAP- 
negative cells. The knock-out of either BLP1 or BLP2 genes of the A. baumannii ST1 AYE 
strain severely affected biofilm formation, as measured by comparing biofilm biomass and 
thickness, and adherence to epithelial cells. The above data suggest that multiple proteins 
sharing Ig-like repeats contribute to biofilm formation in Acinetobacter species. The uneven 
distribution of the different BAP types, BLP1, and BLP2 is highly indicative that alternative 
protein complexes involved in biofilm formation are assembled in different A. baumannii 
strains. 
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Riassunto 
Acinetobacter baumannii è un importante patogeno nosocomiale diffuso a livello mondiale, 
associato ad infezioni cliniche che sono difficili da trattare a causa dall'ampia resistenza 
antimicrobica. Le epidemie di A. baumannii sono causate sia da un numero ristretto di ceppi 
diffusi in tutto il mondo, appartenenti ai cloni inizialmente denominati Europei, ma ora 
considerati cloni Internazionali (IC) I, II ed III sia da pochi cloni epidemici 
recentemente emersi in alcune regioni, come i sequence types (ST)10, ST15, ST25, ST78 and 
ST79 secondo lo schema di tipizzazione mediante multilocus sequencing typing (MLST) 
dell’Istituto Pasteur. 
Il primo capitolo di questa tesi analizza l’epidemiologia genomica di 19 ceppi di A. 
baumannii appartenenti al complesso clonale emergente ST25. Sette genomi con genotipo 
(ST)25 sono stati sequenziati e confrontati a 12 genomi con genotipo ST25 depositati in 
pubbliche banche dati. Un’analisi di ricombinazione ha identificato regioni genomiche 
multiple le quali sono omeoplastiche nella filogenesi del complesso clonale ST25, indicando 
ricombinazioni attive o passate. Geni associati con la resistenza antimicrobica sono 
differentemente distribuiti tra i genomi di ST25, risultato che è in accordo con l’analisi di 
suscettibilità agli agenti antimicrobici effettuata in laboratorio. Tra gli isolati ST25 sono state 
osservate anche differenze nella formazione di biofilm; questi isolati mostrano produrre 
significativamente più biofilm rispetto a un isolato appartenente al complesso clonale ST1. 
Questi risultati dimostrano che all’interno di A. baumannii, anche un derivato monofiletico 
abbastanza recente può ancora mostrare una significatività genotipica e fenotipica. I nostri 
dati dimostrano inoltre che la tipizzazione dei ceppi a livello genomico è importante per 
identificare i meccanismi responsabili della propagazione globale delle linee clonali di A. 
baumannii. 
I ceppi di A. baumannii, secondo il loro profilo di suscettibilità antimicrobica, possono 
essere classificati come multi-resistenti (MDR), estensivamente resistenti (XDR) e totalmente 
resistenti (PDR) se sono rispettivamente resistenti a tre o più, a tutti tranne uno o due, e a tutte 
le classi di agenti antimicrobici potenzialmente efficaci. Attualmente, la diffusione  di ceppi 
di A. baumannii  MDR e XDR è un problema emergente in tutto il mondo. I ceppi 
epidemici sono resistenti ai carbapenemi e mostrano una resistenza intermedia alla
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tigeciclina, ma di solito risultano suscettibili alla colistina. Il secondo capitolo di questa tesi 
descrive l’epidemiologia molecolare di 194 ceppi di A. baumannii resistenti ai 
carbapenemi (CRAB) isolati casualmente da singoli pazienti nel corso del 2015 da 11 ospedali 
terziari situati in tutta la Grecia. CRAB isolati erano MDR o XDR, gli antibiotici 
farmacologicamente più attivi risultavano essere il trimetoprim/sulfametossazolo (SXT) 
(34,6% degli isolati suscettibili), la minociclina (71,6%), la colistina (72,7%) e la tigeciclina 
(valori di MIC50/90, 1/2mg/L). Il gene blaOXA-23 è stato identificato in 188 isolati (96,9%), 
blaOXA-23-like insieme a blaOXA-58-like in 3 isolati (1,5%), blaOXA-58-like in 2 isolati 
(1,0%) e blaOXA-40-like in 1 isolato (0,5%). In tutti gli isolati ISAba1 è stato trovato a monte 
del gene blaOXA-23-like. Il clone internazionale (IC) 2 comprende 157 isolati (80,9%), IC1 
comprende 36 isolati (18,6%) e ST78 comprende 1 isolato (0,5%). Tutti gli isolati 
appartenenti al clone Internazionale (IC)2 e IC1 sono stati genotipizzati mediante MLST e 
corrispondevano rispettivamente al genotipo ST2 e ST1. Sono stati individuati sette profili di 
PFGE. Gli isolati IC2 erano resistenti a più antibiotici rispetto a IC1, ad eccezione di SXT. 
Questo studio nazionale ha mostrato che negli ospedali Greci gli isolati CRAB producono 
quasi uniformemente la carbapenemasi OXA-23 e appartengono principalmente a IC2 e, in 
misura minore, a IC1. Di particolare preoccupazione risulta essere la ridotta suscettibilità 
all’antibiotico colistina. 
La diffusione di batteri gram-negativi estensivamente resistenti ai farmaci (XDR) ha 
determinato un aumento dell’impiego della colistina, con una conseguente selezione di ceppi 
colistina-resistenti, spesso ceppi totalmente resistenti. Se l'acquisizione di ulteriori 
meccanismi di resistenza si traduce in una ridotta virulenza è oggetto di ricerca attiva. Il terzo 
capitolo della tesi analizza le caratteristiche fenotipiche e genotipiche, i meccanismi 
molecolari della resistenza alla colistina e la fitness in vitro e in vivo di ceppi A. baumannii 
colistina-suscettibili e colistana-resistenti isolati da un paziente immunocompromesso che ha 
sviluppato l'infezione dovuta ad un ceppo di A. baumannii colistina-resistente, mentre era 
sottoposto per un lungo arco di tempo a una terapia con la colistina. Sia ceppi colistina- 
sensibili che colistina-resistenti erano XDR e hanno mostrato possedere un identico genotipo 
ST78. A differenza di precedenti relazioni su ceppi di A. baumannii colistina-resistenti, la 
resistenza alla colistina dovuta alla mutazione P233S nel sensore chinasi PmrB non è 
associata con nessuna riduzione misurabile della fitness, delle caratteristiche di crescita e della 
virulenza. 
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Oltre all’ estesa resistenza antimicrobica, i ceppi di A. baumannii responsabili di 
epidemie mostrano un'elevata resistenza all'essiccazione, un'elevata capacità di formare 
biofilm sulle superfici abiotiche e adesione alle cellule epiteliali dell'ospite, 
caratteristiche correlate alla virulenza che potrebbero aver favorito la diffusione e la 
persistenza nell’ambiente ospedaliero. Come in altri microrganismi anche in A. baumannii, la 
formazione di biofilm è un processo multifattoriale che coinvolge diverse componenti. Una 
grande proteina chiamata BAP (biofilm-associated protein) svolge un ruolo nella formazione 
di biofilm e nell'adesione alle cellule dell’ospite in A. baumannii. La maggior parte delle 
proteine BAP è formata da un insieme di moduli di 80-110 amminoacidi caratterizzati da 
domini immunoglobulino-simili (Ig-like). Il quarto capitolo della tesi analizza 
l'organizzazione delle sequenze codificanti BAP in ceppi completamenti sequenziati in 
una ampia collezione di sequenze genomiche di A. baumannii e di altre specie di 
Acinetobacter. Nelle analisi “in silico” è emerso che BAP era altamente polimorfica, 
distinguibile in tre tipi principali per modifiche sia nelle regioni ripetute che nella regione 
COOH terminale. Due proteine addizionali, BLP1 e BLP2 (per BAP-like proteina), 
strutturalmente correlate a BAP, perché contengono domini immunoglobulino-simili, sono 
state identificate tra le specie di Acinetobacter. La BLP1 è mancante nella maggior parte 
dei ceppi che contengono la BAP di tipo-3. BLP2 è in gran parte conservata, ma è spesso 
assente nei ceppi in cui non è presente la BAP. L'eliminazione nel ceppo A. baumannii 
AYE con genotipo ST1 di entrambi i geni BLP1 o BLP2 ha gravemente influenzato la 
formazione di biofilm, misurata confrontando la biomassa e lo spessore del biofilm e 
l'aderenza alle cellule epiteliali. I dati suggeriscono che molteplici proteine che 
condividono ripetizioni Ig-like contribuiscono alla formazione di biofilm nelle specie di 
Acinetobacter. La distribuzione non omogenea dei differenti tipi di BAP, BLP1 e BLP2 è 
altamente indicativa che i complessi proteici alternativi coinvolti nella formazione del 
biofilm sono assemblati in diversi ceppi di A. baumannii. 
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Chapter 1 
Introduction 
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1.1 Acinetobacter genus 
The Dutch microbiologist Beijerinck first isolated the organism in 1911 from soil using 
minimal media enriched with calcium acetate [1]. Originally described as Micrococcus calco- 
aceticus, the genus Acinetobacter (coming from the Greek “akinetos,” meaning non-motile) 
was proposed by Brisou and Prevot in 1954 to separate the motile organisms within the genus 
Achromobacte [2]. The genus Acinetobacter is now defined as including Gram-negative 
coccobacilli, with a G+C content of 39–47%, that are strictly aerobic, non-motile, catalase 
positive, and oxidase negative [3]. Using DNA-DNA hybridization technique, the 
Acinetobacter genus consists of more than 33 species with valid names and at least ten 
genomic species (http://www.bacterio.net/acinetobacter.html, last accessed June 2014) [4]. 
Because phenotypic Identification of Acinetobacter isolates to the species level using 
phenotypic methods is difficult, several genotypic methods have been developed for genomic 
species identification, which include amplified 16S rRNA gene restriction analysis, high- 
resolution fingerprint analysis by amplified fragment length polymorphism, sequence 
analysis of the 16S–23S rRNA gene spacer region, rpoB sequencing and gyrB multiplex PCR 
[3,6-10]. Strains belonging to these species are genetically and phenotypically very similar to 
an environmental species, Acinetobacter calcoaceticus, and thus are often grouped together 
into the so-called  A. calcoaceticus–Acinetobacter baumannii complex [4]. The most clinically 
successful species of the genus are A. baumannii (genospecies 2), A. pittii (genospecies 3) 
and A. nosocomialis (genospecies 13TU) [5]. The species that is most frequently recognized 
as a pathogen is A. baumannii, which causes a variety of healthcare-associated infections, 
comprising hospital-acquired and ventilator-associated pneumonia, bacteremia, urinary tract 
infection and surgical-site infection, especially in intensive care unit patients [5]. 
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1.2 Acinetobacter baumannii 
A. baumannii is a glucose-non-fermentative, Gram-negative coccobacillus, it is ubiquitous 
in nature and has been recovered from soil, water, animals, and humans. A. baumannii 
have emerged in recent years as a major cause of nosocomial infections associated 
with high morbidity and mortality. The capability to survive in dry conditions and resistance 
to disinfectants and antimicrobial agents contribute to the selection of A. baumannii in the 
hospital setting [5,11,12]. Although A. baumannii   has been classically recognized as a 
hospital-acquired pathogen, an increased prevalence of multidrug-resistant A. baumannii 
isolates has been observed among older adults in community hospitals and nursing homes in 
the USA [13]. A. baumannii infections are often associated with epidemic spread, and 
outbreak strains are frequently multidrug resistant (MDR). A most concerning development 
is the increasing occurrence of strains resistant to carbapenems or even to last resource 
antimicrobial agents including colistin or the new antibiotic tigecycline [14]. 
1.3 Molecular epidemiological of Acinetobacter baumannii 
A. baumannii is a globally distributed nosocomial pathogen. Infections caused by A. 
baumannii are increasing worldwide, due to the rapid expansion of a selected number of 
genetically distinct lineages [15,16]. Three of these lineages, known as international clones I 
to III, represent globally distributed and ubiquitous clades [17]. Other successful lineages, 
which spread in single institutions and/or worldwide, have been identified in the population 
structure of  A. baumannii using different genotyping methods, such as such as the sequence 
types (ST)10, ST15, ST25, ST78 and ST79 according to Pasteur’s multilocus sequencing 
typing (MLST) scheme. The population structure of A. baumannii has been studied using 
two MLST nomenclatures, which complicates advances of the epidemiological and 
population biology knowledge of this important pathogen [17,18,19]. The Oxford’s MLST 
database assigned  A. baumannii strains to 1584 different STs; similarly, the Pasteur’s 
MLST scheme assigned A. baumannii strains to 1076 different STs (https://pubmlst.org/
abaumannii/, last accessed July 2017). eBURST analysis [20] can group the Oxford’s STs 
and the Pasteur’s STs into at least 21 and 20 clonal complexes (CCs), 
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respectively, of which ten are corresponding and delineates ten distinct clonal lineages that 
spread in single institutions and/or worldwide (Table 2). In fact, international clone I and 
more recently international clone II prevailed worldwide; international clone III, CC10, 
CC15, CC32, ST25 and ST52 of Pasteur’s MLST scheme were isolated in different European 
countries; CC79 of Pasteur’s MLST scheme was isolated in Brazil and Spain; and ST78 of 
Pasteur’s MLST scheme was isolated in several Italian hospitals. Additional typing 
techniques, such as the tri-locus sequencing-based typing and DiversiLab PCR-based typing 
schemes, are useful tools also to identify A. baumannii  clonal lineages [16]. 
Table 2. A. baumannii  clonal lineages 
AFLP 
Pasteur’s 
MLST 
Oxford’s 
MLST 
blaOXA51-like SBT 3LST DiversiLabTM 
I CC1 (23) CC109 (26) blaOXA-69 SG2 WW1 
II CC2 (55) CC92 (69) blaOXA-66 SG1 WW2 
III CC3 (5) CC106 (5) blaOXA-71 SG3 WW3 
CC25 (11) CC110 (19) blaOXA-64 SG4 WW7 
Cluster A CC15 (11) CC103 (10) blaOXA-51 SG5 WW4 
CC78 (2) CC944 (5) blaOXA-90 SG6 WW6 
Cluster B CC10 (6) CC447 (12) blaOXA-128 WW8 
Cluster 6 CC32 (5) CC472 (3) blaOXA-100 
Cluster C CC52 (3) CC931(3) blaOXA-98 
CC79 (10) CC113 (15) blaOXA-65 
Modified by Zarrilli et al, Int J Antimicrob Agents, 41,11-19, 2013 
13 
1.4 Antimicrobial resistance in Acinetobacter baumannii 
Resistance to antimicrobial agents is the main advantage of A. baumannii in the nosocomial 
environment. A. baumannii possesses several mechanisms of resistance to all existing 
antibiotic classes as well as a striking capacity to acquire new determinants of resistance. 
Resistance mechanisms involve antimicrobial-degrading enzymes, efflux pumps, target 
modification and porin deficiency. The acquisition of antimicrobial resistance can be 
supported by mobile genetic elements (plasmids, transposons and integrons) [5]. 
According to the actual antimicrobial susceptibility profile,  A. baumannii strains can be 
classified as multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug- 
resistant (PDR) if they are resistant to three or more, all but one or two, and all classes of 
potentially  effective  antimicrobial  agents,  respectively  [21].  Molecular  mechanisms  of 
antimicrobial resistance in MDR, XDR and PDR A. baumannii  are shown in Table 3 [22]. 
MDR and XDR in A. baumannii is now an emerging issue worldwide. Strains responsible 
for epidemics are resistant to carbapenems and show intermediate resistance to tigecycline, 
but usually retain susceptibility to colistin [16,23,24]. Colistin often constitutes the only active 
treatment  alternative  [25].  Colistin  is  rapidly  bactericidal  for  Gram-negative  bacteria, 
affecting the lipid A moiety of lipopolysaccharide (LPS) and thus disorganizing the outer 
membrane [26]. During the last few years, clinical isolates of A. baumannii expressing 
resistance to colistin have emerged, and outbreaks have been reported. The emergence of 
colistin resistance has been correlated with the selective pressure exerted by prolonged 
exposure to this drug [27,28]. 
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Table 3. Mechanismis of antimicrobial resistance in MDR, XDR and PDR 
A.baumannii 
 Durante et al. Future Microbiol. 9(6), 773–789, 2014 
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1.5 Virulence determinants 
Despite extensive research into the virulence potential of this emerging pathogen, few studies 
are available on the virulence traits and pathogenic potential of A. baumannii. A. baumannii 
strains responsible for epidemics show elevated resistance to desiccation, high biofilm- 
forming capacity on abiotic surfaces and adherence to host epithelial cells, virulence-related 
features which might have favored the spread and persistence in the hospital environment [29]. 
It has been reported that A. baumannii can form biofilms on several abiotic surfaces, 
including polystyrene, polypropylene, polytetrafluoroethylene and glass. Cells forming 
biofilms are embedded within a polymeric conglomerate of proteins and polysaccharides. 
Biofilms are resistant to host immune defenses, detergents and antibiotics, and antibiotic 
resistance of microrganisms in these habitats can be increased up to a thousand-fold [30]. 
Biofilm formation in A. baumannii has been shown to be positively correlated with the 
expression of chaperone–usher type I pili assembly system, the outer membrane protein 
OmpA, the extracellular polysaccharide poly-b-(1,6)-N-acetyl glucosamine (PNAG), a 
homolog of the staphylococcal biofilm-associated protein (BAP). Also, A. baumannii is able 
to form a tight biofilm structure at air-liquid interface, which is generally referred as pellicle 
and is associated with the presence of poly-Nacetylglucosamine (PNAG) polysaccharide and 
csuA/B usher protein of pili assembly system. Moreover, genes involved in motility, iron 
acquisition, quorum sensing and those encoding efflux system components such as RND 
efflux pump AdeT are over-expressed during biofilm growth of A. baumannii. Virulence 
determinants involved in biofilm growth, including OmpA, BAP, regulate adherence/invasion 
of A. baumannii to host epithelial cells, thus explaining the correlation between biofilm 
formation and adherence to host epithelial cells found in epidemic A. baumannii isolates 
[31-39]. 
The ability of A. baumannii strains to survive for a long time on dry surfaces is likely to 
contribute to their persistence in hospitals [39] . In this respect, it has been reported that 
RecA protein is involved in general stress response and resistance to heat shock and 
desiccation in A. baumannii  [40]. 
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Chapter 2 
Phylogenetic and genetic diversity within ST25 Acinetobacter baumannii; the 
propagation of a clonal lineage with non-clonal behavior 
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Acinetobacter baumannii is a globally distributed nosocomial pathogen that has gained interest 
due to its resistance to most currently used antimicrobials. Whole genome sequencing (WGS) and 
phylogenetics has begun to reveal the global genetic diversity of this pathogen. The evolution 
of A. baumannii has largely been defined by recombination, punctuated by the emergence and 
proliferation of defined clonal lineages. In this study we sequenced seven genomes from the sequence 
type (ST)25 lineage and compared them to 12 ST25 genomes deposited in public databases. A 
recombination analysis identified multiple genomic regions that are homoplasious in the ST25 
phylogeny, indicating active or historical recombination. Genes associated with antimicrobial 
resistance were differentially distributed between ST25 genomes, which matched our laboratory- 
based antimicrobial susceptibility typing. Differences were also observed in biofilm formation 
between ST25 isolates, which were demonstrated to produce significantly more extensive biofilm 
than an isolate from the ST1 clonal lineage. These results demonstrate that within A. baumannii, 
even a fairly recently derived monophyletic lineage can still exhibit significant genotypic and 
phenotypic diversity. These results have implications for associating outbreaks with sequence typing 
as well as understanding mechanisms behind the global propagation of successful A. baumannii 
lineages. 
 
 
Acinetobacter baumannii is an emergent nosocomial pathogen of increasing interest due to its widespread 
resistance to antimicrobials1. A. baumannii is truly a global pathogen, with isolates collected from hospi- 
tals around the world2,3, including injured soldiers from Iraq4 and Afghanistan5. The concern is the emer- 
gence of multidrug-resistant (MDR)6 and extremely drug-resistant (XDR)7 isolates that are resistant to 
most currently used therapeutics. Genes that confer resistance in A. baumannii have been documented, 
including class D beta-lactamases8, such as blaOXA-51-like, which appears to be highly conserved across A. 
baumannii9. The insertion element ISAba1 is required for carbapenem resistance in blaOXA-51-like positive 
isolates10. 
The genome of A. baumannii is highly plastic11, with much of the evolution characterized by recombi- 
nation12 and horizontal gene transfer13. The core genome phylogeny of A. baumannii demonstrates highly 
divergent genomes, with the emergence of a few highly successful clonal lineages12,14. While the evolution 
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Isolate Year/Country Isolate Source Pasteur STa Oxford STb Reference 
RUH 1486 1985/Netherlands Umbilicus 25 229 
Diancourt et al., 
2010 
NM3 2008/UAE Sputum 25 229 Sonnevend et al. 
2013 
LUH 14601 1996/Singapore Respiratory Tract 25 not typed Unpublished 
LUH 6220 2000/Netherlands Sputum 25 not assigned Unpublished 
PV38/LUH 13606 2007/Italy Upper Respiratory tract 25 not typed Carretto et al. 
2010 
LUH 7841 2002/Netherlands venuous catheter tip 402 229 Unpublished 
4390 2003/Greece Bronchial 25 not assigned Gogou et al. 2011 
66492 2012/Argentina Blood 25 110 Stietz et al. 2013 
AO-471 2005/Thailand Wound 25 not typed Karah et al. 2011 
741019 2011/Argentina Pleural fluid 25 not assigned Stietz et al. 2013 
66295 2012/Argentina Blood 25 110 Stietz et al. 2013 
NM133 2008/UAE Bronchial aspirate 25 110 Sonnevend et al. 
2013 
3890 2003/Greece Bronchial aspirate 25 not assigned Di Popolo et al. 
2011 
3865 2005/Turkey Blood 25 440 Di Popolo et al. 
2011 
AO-21841 2006/Sweden Intra-abdominal isolate 25 not typed Karah et al. 2011 
65904 2009/Argentina Inwelling catheter 25 not typed Stietz et al. 2013 
161/07 2007/Germany Respiratory Tract 25 440 Bonnin et al. 2012 
SLO 2008/Slovenia Respiratory Tract 25 not typed Bonnin et al. 2012 
4190 2009/Italy Blood 25 not assigned Zarrilli et al. 2011 
 
Table 1. Metadata associated with ST25 isolates analyzed in this study. aST assigned using 
Pasteur’sMLST scheme (Diancourt et al. 2010) bST assigned using Oxford’s MLST scheme (Bartual et al. 
2005) 
 
 
 
 
of these lineages is anticipated to be clonal, no in depth evolutionary studies have been performed to look 
at the fine scale evolution, recombination, and gene composition of these clades. 
Infections caused by A. baumannii are increasing worldwide, possibly due to the rapid expansion of 
a selected number of genetically distinct lineages12,14. Three of these lineages, known as international 
clones I to III, represent globally distributed and ubiquitous clades15. Other successful lineages, which 
spread in single institutions and/or worldwide, have been identified in the population structure of A. 
baumannii using different genotyping methods, including sequence type ST2514. A. baumannii strains 
assigned to ST25 were responsible for epidemics in different European countries16–20 and the United Arab 
Emirates21 and were isolated as endemic or sporadic isolates in South America22 and Asia18, respectively. 
ST25 genomes are of increasing interest due to increasing antimicrobial resistance14 found within novel 
genomic resistance elements23. 
The aim of the current study was to analyze the genomic epidemiology of 19 A. baumannii strains 
belonging to the ST25 lineage according to Pasteur’s MLST scheme15. Understanding the composition 
and evolution of one successful global lineage may help in understanding the genetic basis for the emer- 
gence and proliferation of global clones of A. baumannii. 
Methods 
Isolates. The collection of ST25 isolates analyzed in  this study  includes 19 strains: three sporadic 
strains from Leiden’s collection isolated during 1985, 2000 and 2002; 13 strains representative of epidem- 
ics or endemic circulation in different countries; three additional sporadic isolates selected because of 
their antimicrobial susceptibility profile and mechanisms of antimicrobial resistance15–22 (Table 1). Seven 
of these isolates were chosen for sequencing. 
 
Pulsed-field gel electrophoresis (PFGE) typing and dendrogram analysis. ApaI DNA macrore- 
striction and PFGE of A. baumannii isolates were performed as previously reported24. PFGE profiles were 
compared using the GelCompar II v. 4.6 software package (Applied Maths, Sint-Martens-Latem, Belgium). 
Clustering was based on the un-weighted pair-group method with arithmetic averages (UPGMA). The 
Dice correlation coefficient was used to analyze the similarities of the banding patterns with a tolerance 
of 1%. Interpretation of chromosomal DNA restriction patterns was based on the criteria of Tenover et 
al.25 and also on a similarity of >85% at dendrogram analysis, to indicate strain relatedness. 
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MLST typing. Multi-locus sequence typing (MLST) analysis was performed using the Institut Pasteur’s 
MLST scheme as previously described15. Allele sequence and MLST profile definitions were 
assigned using the sequence and profile definitions available at http://pubmlst.org/abaumannii/. The 
MLST results were confirmed from the whole genome sequence analysis using a publically available 
script: https:// github.com/Victorian-Bioinformatics-Consortium/mlst. 
 
DNA extraction, sequencing, assembly. DNA was extracted with the GenElute DNA extraction 
kit (Sigma-Aldrich, Milan, Italy). Sequence libraries were generated from extracted DNA as reported 
previously9. Genomes were sequenced to high depth on the IlluminaMiSeq platform. Resulting reads 
were adapter trimmed with Trimmomatic26, error corrected with Hammer27, and assembled with SPAdes 
v3.128. The read coverage across each contig was evaluated, and contigs of an anomalous coverage, due 
to read crossover in multiplexed runs, were manually removed. The assembly stats for each genome 
are shown in Supplementary Table S1. All assemblies and raw reads were deposited in public data- 
bases (accession numbers in Supplementary Table S1). Annotation was performed with the NCBI PGAP 
pipeline. 
 
Antimicrobial susceptibility testing. Antimicrobial susceptibility testing was performed using the 
Vitek 2 system (bioMérieux, Marcy l’ Étoile, France). Imipenem, meropenem and colistin minimum 
inhibitory concentrations (MICs) were determined by agar dilution and Etest (bioMérieux) and inter- 
preted using the EUCAST29 and CLSI 201230 interpretative criteria. 
 
in silico antimicrobial susceptibility profiling. To identify previously characterized genes associ- 
ated with antimicrobial resistance in our dataset, raw reads were mapped to the ResFinder database31 
with the SRST2 pipeline32; raw reads were used to determine the percentage of the reference gene cov- 
ered, but also could identify variants compared to the reference database. SRST2 produces a table of all 
positive hits identified in each genome. 
 
Biofilm formation. Biofilm formation was determined as previously described55. Three independent 
experiments, each one performed in triplicate, were conducted for each strain. Biofilms were grown in 
the presence and absence of 0.5 mg/L imipenem. 
 
Cell adhesion assays. Adherence of A. baumannii strains to A549 cells (human type 2 pneumo- 
cytes) was determined as described previously55, with minor modifications. In brief, ~105 A549 cells 
were infected with ~107 bacterial CFU and incubated for 60 min at 37 °C in 5% CO2 (v/v) atmosphere. 
Non-adherent bacterial cells were removed by washing with PBS. Infected cells were lysed by the addi- 
tion of 1 ml distilled water and serial 10-fold dilutions were plated on LB agar to determine the number 
of CFU of adherent bacteria. To determine adherent and invading bacteria, A549 cells were infected with 
A. baumannii strains as described above. The monolayers were then treated with 1 ml of fresh culture 
medium containing 5 mg/L of colistin sulfate (Sigma-Aldrich, Milan, Italy) for 30 min, the shortest time 
point that resulted in the killing of all extracellular bacteria added to the monolayers. Afterwards, the 
cells were washed with PBS, harvested with trypsin, and lysed with sterile distilled water. Dilutions from 
harvested samples were inoculated on LB agar plates and bacterial colony counts were estimated after 
overnight incubation at 37 °C. Each experiment was performed in triplicate. 
 
Statistical analysis.    Data were analyzed using a Statistical Package for the Social Sciences Version 
13.1 (SPSS Inc., Chicago, IL, USA). Differences between mean values were tested for significance 
by performing either unpaired, two-tailed Student’s t-tests or one-way ANOVA analysis followed by 
Tukey’s multiple-comparison test, when appropriate. A P value< 0.05 was considered to be 
statistically signif- icant. Correlations were evaluated by regression analysis using the Pearson’s 
correlation coefficient (r). 
 
Single nucleotide polymorphism (SNP) identification and phylogenetics. For ST25 compari- 
sons, all SNPs were identified by mapping raw reads against A. baumannii AB307-0294 (NC_011595)33 
with BWA-MEM34 and calling SNPs with the UnifiedGenotyper method in GATK35. For external genome 
assemblies, whole genome alignments were generated with nucmer36  and variants were identified by 
direct mapping of each query to the reference. These methods were wrapped by the Northern Arizona 
SNP Pipeline (NASP) (http://tgennorth.github.io/NASP/)37. A phylogeny was inferred from the resulting 
concatenated SNP alignment with a maximum likelihood algorithm in RaxML v838. The Retention Index 
(RI) value39, which demonstrates how consistent the nucleotide character states are with the phylogeny, 
was calculated with Phangorn40. 
For the global A. baumannii phylogeny, a set of 572 reference genomes (Supplementary Table S2) were 
downloaded from Patric41. Genome assemblies were aligned against AB307-0294 with NASP. A maxi- 
mum likelihood phylogeny was inferred on this alignment with RaxML. Genomes were pruned from the 
phylogeny to only reflect the major sequence types. Clades were collapsed in ARB42. 
 
LS-BSR analysis. To look for differential gene conservation, the Large-Scale Blast Score Ratio (LS- 
BSR) pipeline43  was employed. In this method, all coding regions (CDSs) predicted by Prodigal44 
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are clustered with USEARCH45 at an ID of 90%. Each resulting centroid, which is the most representative 
sequence of each cluster, is then aligned against itself with BLAT46 to obtain the reference bit score. Each 
centroid is then separately aligned against each genome assembly with BLAT to obtain the query bit 
score. Dividing the query bit by the reference bit score returns the BLAST Score Ratio (BSR)47. Unique 
genomic regions were identified by comparing all CDSs between groups and considering a region to be 
unique if it had a BSR value> 0.8 in target genomes and a BSR value< 0.4 in all non-target genomes. 
Recombination analysis. The FASTA output of NASP was converted to NEXUS using Readseq48. 
The Retention Index for each base was then calculated with Paup v4a14049; the specific Paup commands 
are publicly available (https://gist.github.com/jasonsahl/a66afa55371d7d916a0e). The SNP density (SD), 
or number of parsimony-informative (PI) SNPs across a genomic interval, was calculated across 1-Kb, 
non-overlapping windows, compared to the reference genome of A. baumannii AB307-0294; PI SNPs are 
those that that contain at least two types of nucleotides and occur in a minimum of two genomes. The 
number of homoplasious SNPs, based on a per-base RI value< 0.5, was also calculated across the same 
window. The Homoplasy Density (HD) value was calculated by dividing the number of homoplasious 
SNPs (those SNPs that are inconsistent with the tree topology) by the total number of PI SNPs; a script to 
perform these functions has been published previously50. Visualization was performed by Circos51. Core 
genome regions, or those regions conserved across all genomes tested, were identified from the NASP 
output, where a call was made in all genomes. 
Plasmid analysis. CDSs predicted by Prodigal for 40 plasmids identified in A. baumannii 
(Supplementary Table S3) were mapped across ST25 genomes with LS-BSR and BLAT. Following 
man- ual curation of screened CDSs, the conservation of genes in associated plasmids was visualized 
with the interactive tree of life52. Only a subset of CDSs was selected to demonstrate the variability 
in plasmid content across isolates. 
Gene screen. The distribution of several genes associated with virulence or antimicrobial resistance 
was determined across all ST25 genomes. This included AbaR1, which has previously been shown to be 
missing from A. baumannii 419053. This region (Coordinates 3702770-3602770 in A. baumannii AYE) 
was parsed out of A. baumannii AYE and coding regions were predicted with Prodigal. Other resistance 
islands, including AbaR4 (JN107991) and the G7 plasmid that contains AbaR3 (KF669606) were also 
screened. All CDSs were then compared against all ST25 genomes with LS-BSR and BLAT. An 
additional set of genes previously associated with virulence in A. baumannii (Supplementary Table 
S4) was also screened against ST25 genomes with LS-BSR. 
Results 
Isolates analyzed.   In addition to ST25 genomes deposited in public databases, we selected a set 
of isolates to expand the diversity of this global lineage. The following seven isolates in our collection 
were selected for WGS analysis in addition to WGS data of strain 4190 already available in GenBank54: 
strains RUH1486 and NM3 are susceptible and MDR epidemic isolates, respectively; carbapenem-resist- 
ant strains 4390 and 741019 carry different carbapenemase genes (blaOXA-58 versus blaOXA-23) but both 
belong to the major PFGE type E (Fig. 1), isolated during epidemics in different countries (Table 1); 
strain 161/07 contains a distinct carbapenemase (NDM-1); strain LUH6220 has a MDR phenotype but 
is susceptible to carbapenems; strain LUH7841 is susceptible to most antimicrobials (Supplementary 
Table S5). 
PFGE Analysis. PFGE analysis identified ten unrelated PFGE types (A-J), with six PFGE subtypes 
within these types (Fig. 1) (C1, E1-E4, I1). Interestingly, PFGE type A included the susceptible first iso- 
late of our collection (RUH1486) and the NM3 MDR strain isolated during an epidemic in United Arab 
Emirates; six strains from Greece, Argentina, Sweden or Abu Dhabi Emirates were assigned to PFGE 
type E or PFGE subtypes E1-E4, while two XDR isolates from Argentina and Sweden showed identical 
PFGE type H (Table 1 and Fig. 1). 
MLST. MLST with the Pasteur system15 was performed on 19 ST25 genomes, although only 7 were 
subjected to whole genome sequencing (WGS). Of all ST25 isolates analyzed, including a set of reference 
genomes from GenBank, eighteen were assigned to ST25, while one to ST402 (LUH7841), which is 
a single-locus variant of ST25. In silico MLST confirmed sequence type assignments for all genomes 
where WGS data exists (Supplementary Table S1). 
Antimicrobial susceptibility testing. The antimicrobial susceptibility profiles of 19 ST25 A. bau- 
mannii strains included in the study are shown in Supplementary Table S5. Two strains were classified 
as susceptible, six and eleven as MDR and XDR, respectively, according to Magiorakos et al., 201229. 
Five out of six MDR strains and all 11 XDR strains showed resistance to carbapenems and contained 
class D or class B carbapenemases. 
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Figure 1.  Genotypic analysis of PFGE profiles of A. baumannii strains included in the study. Percentage 
of similarity at dendogram analysis and position and tolerance values of the DICE correlation coefficient used 
in clustering are shown. Sizes in kilobases (kb) of lambda DNA molecular mass markers are indicated    
above the PFGE profiles. Strain number, year/country of isolation, PFGE types and subtypes and Multi-locus 
Sequence types are shown on the right of each profile. 
 
      
 
Genome 
Resistanc
e 
phenotype 
 
Aminoglycosides 
 
Beta-lactams 
 
Sulfonamides 
 
Tetracyclines 
4390 XDR X07753 (aphA6) blaOXA-64 N/A N/A 
 
161/07 
 
MDR 
JN119852 (aadB), 
DQ336355 (OrfA), 
X00753 (aphA6), M96392 
(tnpA) 
 
blaNDM-1, blaOXA-64 
 
GQ421466 (glmM) 
 
N/A 
741019 MDR X57709 (aphA2), M96392 
(tnpA) 
blaOXA-64, blaOXA-23 GQ421466 (glmM) AP000342 (tetA) 
LUH7841 Susc. N/A blaOXA     
*
 
-64 
N/A N/A 
LUH6220 MDR 
X57709 (aphA2), 
DQ336355 (OrfA), 
X07753 (aphA6) 
blaOXA-64, blaOXA-58 N/A N/A 
NM3 MDR X57709 (aphA2), M96392 
(tnpA) 
blaOXA-64, blaOXA-23 GQ421466 (glmM) AP000342 (tetA) 
RUH1486 Susc. N/A blaOXA     
*
 
-64 
N/A N/A 
 
Table 2.   in silico analysis of genes associated with antimicrobial resistance. N/A= no detection *ISAba1 
negative 
 
 
 
In silico antimicrobial resistance profiling. As a complement to the laboratory-determined anti- 
microbial susceptibility profiles, in silico profiles were generated for each sequenced genome, using the 
ResFinder database31 in conjunction with the SRST2 pipeline32. The results demonstrate that resistance 
mechanisms were identified in the genomes tested for only a few classes of antimicrobials (Table 2), 
demonstrating limitations in predicting the resistance phenotype from the genotype. Carbapenemase 
genes were found in the genomes of 161/07 (blaNDM-1, blaOXA-64), 741019 and NM3 (blaOXA-64, blaOXA-
23), and 4390 and LUH6220 (blaOXA-64). The blaOXA-64 gene (AY750907), which is also known as 
blaOXA-51-like, is conserved in all ST25 genomes tested (Table 2). However, the ISAba1 insertion 
sequence is missing in carbapenem-susceptible isolates that are blaOXA-64 positive, while present in 
resistant isolates, which confirms published results that this sequence is required for carbapenem 
resistance10. 
 
Biofilm formation and pneumocyte adherence. Our previous results demonstrated that the abil- 
ity to form biofilm and adherence to cultured pneumocytes was significantly higher for A. baumannnii 
strains assigned to ST25 and ST2 compared to other STs55. The biofilm growth on abiotic surfaces and 
adherence/invasion to cultured A549 pneumocytes were assessed for the 19 strains included in this 
study. As demonstrated in Fig. 2 panel A, the 19 strains assigned to ST25 and ST402 and strain ACICU 
assigned to ST2 generally demonstrated significantly (p < 0.05) greater biofilm growth than strain AYE 
assigned to ST1, although variability in biofilm growth was observed among ST25 strains. Exposure to 
sub-inhibitory concentrations of imipenem significantly (p < 0.05) stimulated biofilm growth in strains 
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Figure 2. Biofilm variation between ST25 genomes, a ST1 genome (AYE), and a ST2 genome 
(ACICU). Error bars represent the standard deviation between biological replicates. Differences in biofilm 
production were calculated with a two-tailed t-test. Isolates were grown in the absence (A) or presence (B) 
of imipenem (0.5 mg/L). 
 
 
 
AYE and ACICU assigned to ST1 and ST2, respectively, but not in the strains assigned to ST25 or 
ST402 (Fig. 2, panel B). We next investigated the ability of A. baumannii strains to adhere to A549 
human alve- olar epithelial cells. All A. baumannii strains assigned to ST25 and ST2 (ACICU) strain 
showed a signif- icantly higher adherence to A549 human bronchial cells compared with ST1 strain 
AYE (Supplementary Fig. S1) (p < 0.01). On the other hand, ST25 A. baumannii strains were not 
able to invade A549 cells human alveolar cells. Also, a similar number of bacteria adhered to A549 
cells when the monolayers were incubated with A. baumannii strains for 60 min at 4 °C, i.e. under 
conditions that do not allow for tissue invasion. 
 
Sequencing and comparative genomics.  WGS  of  seven  strains  was  performed  and  com- 
pared to whole genome sequences of 12 A. baumannii strains assigned to ST25 available in GenBank 
(Supplementary Table S1) and to 572 non-ST25 A. baumannii reference genomes (Supplementary Table 
S2). The core genome phylogeny based on 1.15Mb of conserved sequence demonstrated the position of 
the ST25 lineage (Fig. 3) in relation to other globally-relevant lineages. The retention index (RI) of the 
concatenated SNP alignment was 0.85, demonstrating significant homoplasy likely due to recombination 
and introducing uncertainty in the phylogenetic placement, especially with regards to deeply branching 
nodes and long branches56. A phylogeny of just the ST25 genomes (Fig. 4) also demonstrated homo- 
plasy (RI = 0.84), which demonstrates that although ST25 is a lineage with closely related genomes, the 
evolution of this group has also been partially driven by recombination; the core genome size of ST25 
genomes in relation to AB307-0294 was 3Mb. As anticipated, the core genome phylogeny demonstrated 
much different relationships than were obtained by the PFGE cluster dendrogram (Figs 1 and 4). For 
example, genomes RUH1486 and NM3 both share the same PFGE type (Fig. 1), but are significantly 
different based on the core genome phylogeny (Fig. 4). 
 
Recombination in the ST25 lineage.    To demonstrate both the extent and location of recombination 
in the ST25 lineage in relation to the genome of AB307-0294, a homoplasy density analysis was per- 
formed50. Considering all of the A. baumannii genomes (n = 597), the homoplasy appears to be distrib- 
uted equally across the reference chromosome, with no isolated regions of recombination (Supplementary 
Fig. S2). When only considering the ST25 genomes, clear regions have likely been recombined between 
isolates (Fig. 5, panel A). However, fragments in the core genome, using AB307-0294 as the reference, 
still generally give a strong phylogenetic signal (Fig. 5, panel B). The annotation of selected regions 
associated with recombination is shown in Supplementary Table S6. A comprehensive list of HD values 
across all regions in the reference chromosome is also available (https://gist.github.com/5e1cab0b85c- 
73de7c6d6.git). 
 
Plasmid composition. The horizontal gene transfer of plasmids  was  analyzed  in  ST25  genomes, 
using the composition of 40 previously characterized A. baumannii plasmids (Supplementary Table S3). 
Coding regions were predicted for all the plasmids using Prodigal and they were compared against 
19 ST25 genomes using LS-BSR. The results demonstrate that the plasmid content is highly variable 
across sequenced genomes (Fig. 6), although this method fails to discriminate between genes present on 
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Figure 3.  A core genome single nucleotide polymorphism (SNP) phylogeny of 597 A. baumannii 
genomes. The phylogeny was inferred with RAxML38  from a concatenation of ~104,000 SNPs compared to 
the reference genome of AB307-0294. Sequence types were identified from genome assemblies. Genomes 
without close relatives in established sequence types were manually pruned from the tree and groups were 
collapsed with ARB42. The phylogeny was rooted by first including an outgroup from A. nosocomialis, then 
re-running the analysis with only A. baumannii and rooting on the most basal genome from the original 
analysis. 
 
 
 
 
plasmids or the chromosome. The susceptible genome RUH1486 appeared to not contain any annotated 
plasmid. 
 
Unique genomic regions. The complete genetic content for 597 A. baumannii genomes was com- 
pared using LS-BSR. By using default values in LS-BSR, a single coding region was found to be 
present in ST25 genomes and absent from all others; this region corresponds to a large (~14600 
nucleotides) hemagglutinin repeat protein (WP_002016208.1). While portions of this gene are conserved 
in other A. baumannii genomes, the complete gene structure is unique to ST25 genomes and could 
potentially serve as a diagnostic tool for the surveillance of this global lineage. 
 
Distribution of virulence associated genes. Virulence associated genes (Supplementary Table S4) 
were screened against ST25 genomes with LS-BSR and BLAT. The results demonstrate variability in com- 
position across four genes. Perhaps the most striking difference is in ompF, which is highly conserved in 
only three genomes, each on the same branch of the phylogeny (Supplementary Fig. S3). 
 
Distribution of resistance islands. Coding regions from three previously characterized resistance 
islands were screened against ST25 genomes with LS-BSR. The results demonstrate that AbaR1 and 
AbaR4 were sparsely distributed across ST25 genomes (Supplementary Fig. S4). However, the AbaR3 
resistance island was highly conserved across two lineages in the ST25 phylogeny, likely demonstrating 
independent acquisition. 
 
Discussion. A. baumannii is a globally distributed nosocomial pathogen associated with clinical infec- 
tions that are difficult to treat due to widespread antimicrobial resistance. WGS has begun to demonstrate 
the phylogenetic diversity of this pathogen, which seems largely driven by homologous recombination12. 
28  
 
 
 
 
 
 
 
 
 
LUH7841 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  A core genome single nucleotide polymorphism (SNP) phylogeny of ST25 genomes. The 
phylogeny was inferred with RAxML from a concatenation of ~24,000 SNPs compared to the reference 
genome of AB307-029433  with 100 bootstrap replicates. Each genome was annotated with its antimicrobial 
susceptibility information, where available. The tree was rooted according to the most basal genome isolated 
from the global phylogeny (Fig. 3). 
 
 
 
 
 
 
Figure 5.  Homoplasy density (HD) ratio analysis of ST25 genomes. (Panel A): Parsimony informative 
(PI) single nucleotide polymorphisms (SNPs) were identified across 1-Kb, non-overlapping windows (SNP 
density, or SD), compared to the reference genome of AB307-0294. Homoplasious SNPs were identified by 
a Retention index value < 0.05. The HD was calculated by dividing the number of homoplasious SNPs by 
the total number of PI SNPs. The SD and HD values were visualized with Circos51. Core genome regions 
were identified where there was a call in all query genomes compared to the reference genome. (Panel B): 
The distribution of 1-kb, non-overlapping regions, based on the HD values. 
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Figure 6.  The ST25 phylogeny associated with a heatmap of coding regions predicted from plasmids 
identified in A. baumannii genomes. The heatmap was generated from LS-BSR43 output and was visualized 
with the interactive tree of life52. GenBank accession numbers are listed for each queried coding region. 
 
 
 
And although phylogenetic diversity has been documented, many genomes sequenced to date fall into 
clearly defined clonal lineages, such as ST1 and ST2, which have been identified worldwide14. 
Genetic diversity within each of these sequence types has largely focused on the diversity of 
antimicrobial resist- ance islands57–60 or individual loci61. The focus of this study was to perform a 
comprehensive genomics analysis of the ST25 lineage, which was isolated in different countries and was 
responsible for epidemics worldwide16–22, to better understand the genotypic and phenotypic 
properties behind the worldwide distribution and evolution of a successful lineage of A. baumannii. 
Phenotypic diversity was observed within ST25, including differences in biofilm formation, antimi- 
crobial susceptibility, and pneumocyte adherence. In terms of biofilm formation, ST25 isolates produce 
a significantly higher amount of biofilm than a single ST1 representative in the absence of antimicrobials 
(Fig. 2, panel A). Although the relationship between biofilm formation and virulence has not been solid- 
ified in A. baumannii62, biofilms have been associated with resistance to antimicrobials63, pathogenensis64 
as well as resistance to host factors65. The presence of imipenem did not affect biofilm production in ST25 
isolates, suggesting that these mechanisms are constitutively expressed. 
Antimicrobial susceptibility testing demonstrated varied susceptibility profiles within ST25 isolates 
(Supplementary Table S5). In silico profiles using WGS data against the ResFinder database could pre- 
dict laboratory resistance for only a subset of antimicrobials (Table 2). This demonstrates that although 
antimicrobial resistance databases are useful for predicting resistance for some classes of antimicrobials, 
additional experimentation is required to fully understand the genetic basis for antimicrobial resistance 
in A. baumannii. In terms of adherence, ST25 genomes were demonstrated to adhere better than a rep- 
resentative from the ST1 clonal lineage. Although this may be due to the presence of a unique haemag- 
glutinin identified in ST25 and absent from all other A. baumannii genomes, additional experimentation 
is required. 
The genetic diversity of ST25 was demonstrated in multiple ways, including the visualization of a 
core genome single nucleotide polymorphism (SNP) phylogeny (Figs 3 and 4); a similar topology was 
observed compared to a recent CRISPR-subtyping analysis66. A homoplasy density approach demon- 
strated that much of the SNP density that defines the phylogenetic structure of ST25 is due to homo- 
plasy (Fig. 5, panel A), most likely resulting from homologous recombination. The extent of homoplasy 
observed in the global phylogeny suggests that A. baumannii does not evolve in a tree like manner and 
different methods may better represent the evolution in this highly recombinant pathogen. 
In addition to SNP analyses, comparative genomics demonstrated a much different gene content 
between ST25 genomes, primarily between mobile genetic elements. In the case of plasmids, the gene 
content was significantly different (Fig. 6), which was anticipated due to the movement of mobile genetic 
elements and has been demonstrated previously in Acinetobacter67. However, a screen of genes associated 
with virulence also demonstrated differences between closely related genomes (Supplementary Fig. S3). 
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The variable distribution of genes across the ST25 dataset, including those associated with antimicrobial 
resistance islands (Supplementary Fig. S4), may help explain the variable phenotypes. Overall, these 
results demonstrate the problem with assuming that isolates have similar gene content or phenotypes 
based solely on MLST or PFGE type analyses. In terms of either assigning isolates to outbreaks or under- 
standing the evolution of clonal lineages, WGS offers the resolution to untangle the relationships between 
seemingly related isolates. 
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In a previous nationwide study in Greece, OXA-58 was the sole carbapenemase present among carbapenem- 
resistant Acinetobacter baumannii (CRAB) isolated between 2000 and 2009. In this study, the antibiotic 
resistances, carbapenemase gene content and clonal relatedness of 194 single-patient CRAB clinical iso- 
lates collected randomly during 2015 from 11 tertiary hospitals located throughout Greece were investigated. 
Antimicrobial susceptibility was determined using commercial and dilution methods. PCR assays for 
carbapenemase genes were performed. Clonality was tested by a scheme based on two multiplex PCRs 
and single-locus blaOXA-51-like sequence-based typing. Furthermore, Pasteur’s multilocus sequence typing 
(MLST) scheme and pulsed-ﬁeld gel electrophoresis (PFGE) were applied to 31 selected representative 
isolates. The most active antibiotics were trimethoprim/sulfamethoxazole (SXT) (34.6% of isolates sus- 
ceptible), minocycline (71.6%), colistin (72.7%) and tigecycline (MIC50/90 values, 1/2 mg/L). The blaOXA-23-like 
gene was identiﬁed in 188 isolates (96.9%), blaOXA-23-like together with blaOXA-58-like in 3 isolates (1.5%), blaOXA-58-like 
in 2 isolates (1.0%) and blaOXA-40-like in 1 isolate (0.5%). ISAba1 was found upstream of the blaOXA-23-like gene 
in all isolates. International clone (IC) 2 comprised 157 isolates (80.9%), IC1 comprised 36 isolates (18.6%) 
and ST78 comprised 1 isolate (0.5%). All IC2 and IC1 isolates tested by MLST were ST2 and ST1, respec- 
tively. Seven PFGE types were detected. IC2 isolates were resistant to more antibiotics than IC1, except 
for SXT. This nationwide study showed that CRAB isolates in Greek hospitals currently produce almost 
uniformly the OXA-23 carbapenemase and belong mainly to IC2 and, to a lesser extent, IC1. Of particu- 
lar concern, colistin susceptibility is recently severely reduced. 
© 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved. 
 
 
 
 
1. Introduction 
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tance are listed in the Appendix. 
Acinetobacter baumannii isolates are increasingly causing severe 
infections among debilitated patients, particularly in intensive care 
units (ICUs) [1]. Carbapenem resistance is currently widespread 
among A. baumannii, with rates reaching or exceeding 90% in South- 
ern and Eastern European countries [2]. Carbapenem-resistant A. 
baumannii (CRAB) are commonly resistant to most available anti- 
microbials except colistin, tigecycline and minocycline [3,4]. Tracking 
the evolution and clonal composition of CRAB isolates is impor- 
tant to support the implementation of control strategies. Molecular 
epidemiological studies  usually reveal clonality  of  CRAB,  with 
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outbreak strains usually belonging to international clones (IC) 1 and 
2 and a few additional clonal lineages [5]. 
In Greek hospitals, during the last few years the vast majority 
of A. baumannii isolates are CRAB [2], which currently represent the 
most frequent infection pathogen in the ICU (http://www.mednet.gr/ 
whonet/). Regarding their clonal nature and carbapenemase gene 
content, we showed previously in a Greek nationwide study con- 
ducted from 2000 to 2009 that CRAB were harbouring only the 
OXA-58 carbapenemase gene; IC1 was the most common lineage 
until 2004, with IC2 prevailing during 2005–2009 [6]. 
Studies in several European countries have shown that OXA-23 
tends to gradually replace OXA-58 among CRAB [7,8]. Also, a pre- 
liminary study from a single Greek hospital in 2011 reported that 
OXA-23 was more common than OXA-58 [9]. Given the increased 
frequency and importance of CRAB, the present follow-up nation- 
wide study was conducted to analyse the resistance phenotypes, 
carbapenemase gene content, genetic relatedness and evolution of 
clonal lineages among CRAB recovered from Greek patients during 
2015. 
 
 
2. Materials and methods 
 
2.1. Bacterial strains 
 
During 2015, as many as 2500 A. baumannii isolates were iden- 
tiﬁed in 11 tertiary hospitals located in eight cities in Northern 
(Thessaloniki, Serres, Alexandroupolis), Western (Ioannina), Central 
(Athens, Piraeus, Larissa) and Southern (Heraklion) Greece. The rate 
of CRAB in these hospitals during 2015 was 95%, with virtually all 
clinically important A. baumannii being CRAB. The present study in- 
cluded 194 randomly selected non-repetitive CRAB isolates recovered 
during 2015 from clinical samples in these hospitals. All isolates were 
conﬁrmed to be A. baumannii by PCR/sequencing for the intrinsic 
blaOXA-51-like  gene [10]. 
 
 
2.2. Antimicrobial  susceptibility 
 
The susceptibilities of the isolates to ampicillin/sulbactam 
(SAM), ceftazidime, cefepime, ciproﬂoxacin, levoﬂoxacin, gentami- 
cin, amikacin, tobramycin, tetracycline and trimethoprim/ 
sulfamethoxazole (SXT) were determined using a VITEK®2 system 
(bioMérieux, Marcy-l’Étoile, France). Minimum inhibitory concen- 
trations (MICs) of imipenem, meropenem, minocycline and 
tigecycline were determined by agar dilution, whereas the broth 
microdilution method was used for colistin as recommended re- 
2.4.  Typing by multiplex PCR, blaOXA-51-like sequence-based typing 
(SBT), multilocus sequence typing (MLST) and pulsed-ﬁeld gel 
electrophoresis (PFGE) 
 
Two multiplex PCRs that selectively amplify group 1 or group 
2 alleles of the ompA, csuE and blaOXA-51-like were used as a screen- 
ing method for rapid assignment of isolates to sequence groups (Gs) 
1–3 and 6 as reported previously [17,18]. 
The single-locus blaOXA-51-like SBT  method was also applied to all 
isolates to assign them into ICs [19]. A total of  31 isolates, at least 
1 from each collaborating hospital, selected to represent all se- 
quence groups and combinations of amplicons determined by the 
multiplex PCRs and also the ICs derived by SBT, were subjected to 
the Pasteur’s MLST scheme (http://pubmlst.org/abaumannii/). ApaI 
DNA macrorestriction and PFGE of  the 31 isolates were performed 
as previously described [20]. The PFGE proﬁles obtained were con- 
verted to TIFF ﬁles and were subjected to cluster analysis using 
GelCompar II v.4.6 software (Applied Maths, Sint-Martens-Latem, 
Belgium). Clustering was based on the  unweighted  pair-group 
method with arithmetic averages (UPGMA). The Dice correlation co- 
eﬃcient was used to analyse the similarities of the banding patterns 
with a tolerance of 1.3%. Interpretation of chromosomal DNA re- 
striction patterns was based on the  criteria  of Tenover  et  al.  [21] 
and also on  a similarity of >85% at  dendrogram analysis in  order 
to  indicate  strain  relatedness. 
 
3. Results 
 
3.1. Patient data, susceptibility testing and carbapenemase genes 
 
Of the patients that yielded CRAB, 70.1% were male and 29.9% 
female; most of them were hospitalised in ICUs (56.2%), 20.6% in 
medical wards, 17% in surgical wards, 2.1% in long-term care fa- 
cilities and 4.1% were outpatients. Isolates were obtained from blood 
(45.9%), the respiratory tract (21.6%), skin and soft tissue (11.3%), 
urine (9.3%) and various other clinical samples (11.9%). 
The 194 CRAB isolates showed imipenem and meropenem 
MICs ≥ 32 μg/mL and were non-susceptible to all ﬂuoroquinolones 
and β-lactams tested except SAM (5.2% of isolates susceptible). Sus- 
ceptibility rates to other antibiotics were as follows: gentamicin, 9.4%; 
amikacin, 15.5%; tobramycin, 22.9%; tetracycline, 10.3%; SXT, 34.6%; 
minocycline, 71.6%; and colistin, 72.7%. For tigecycline, MIC50/90 values 
were 1/2 mg/L. Of the study isolates, 3.1% were MDR, 78.4% were 
XDR and 18.6% were PDR. 
The blaOXA-23-like gene was identiﬁed in 188 isolates (96.9%), 
blaOXA-23-like together with blaOXA-58-like in 3 isolates (1.5%), blaOXA-58-like 
in 2 isolates (1.0%) and blaOXA-40-like in 1 isolate (0.5%). ISAba1 
cently by the European Committee on Antimicrobial Susceptibility was  detected  upstream  of  the  bla OXA-23-like gene  in  all  191 
Testing (EUCAST) (http://www.eucast.org/guidance_documents/) and bla -positive isolates (98.5%) and upstream of bla in 
the Clinical and Laboratory Standards Institute (CLSI) [11]. CLSI in- 
terpretative criteria [11] were applied  for the categorisation of 
isolates; for tigecycline, MIC50 and MIC90 values were calculated due 
to the lack of CLSI/EUCAST interpretative criteria for Acinetobacter 
spp.  Multidrug-resistant  (MDR),  extensively  drug-resistant  (XDR) 
OXA-23-like 
44 isolates (22.7%). 
 
 
3.2. Molecular  epidemiology 
OXA-51-like 
and pandrug-resistant (PDR)  isolates were  classiﬁed  as recom- 
mended previously [12]. 
 
 
2.3.  PCR for carbapenemase genes 
 
Genes encoding common class D carbapenemases (blaOXA-51-like, 
blaOXA-58-like, blaOXA-23-like, blaOXA-40-like, blaOXA-143-like) and class B metallo- 
β-lactamases (blaIMP, blaVIM, blaNDM) [13–15] were detected by PCR, 
followed by sequencing of selected amplicons. The presence of ISAba1 
upstream of blaOXA-23-like, blaOXA-58-like and blaOXA-51-like was tested  by 
PCR as described previously [16]. 
The multiplex PCR-based typing scheme assigned the majority 
of isolates (151; 77.8%) to G1 (IC2) and 14 isolates (7.2%) to G2 (IC1), 
whilst 1 isolate (0.5%) was assigned to G6. The remaining 28 iso- 
lates (14.4%) demonstrated three different banding patterns, as 
follows: ampliﬁcation of G1 ompA/blaOXA-66, 6 isolates; ampliﬁca- 
tion of G1 csuE/G2 ompA/blaOXA-69, 21 isolates; and ampliﬁcation of 
G2 ompA/blaOXA-69, 1 isolate. 
Using SBT, 157 isolates (80.9%) belonged to IC2 harbouring 
blaOXA-66, 36 isolates (18.6%) to IC1 (blaOXA-69) and 1 isolate (0.5%) to 
G6 (blaOXA-90). MLST conﬁrmed these group assignments: all IC2 iso- 
lates tested were ST2, all IC1 isolates were ST1 and the isolate with 
blaOXA-90 was ST78. Seven distinct PFGE types were identiﬁed: types 
  
 
 
 
 
% Similarity 
 
 
kb 
 
 
 
 
 
Fig. 1.   Characteristics  and  clonal  composition  of  31  representative  Acinetobacter  baumannii  isolates  tested  using  multiplex  PCR-based  typing,  single-locus  blaOXA-51-like   sequence-based  typing  (SBT),  pulsed-ﬁeld  gel  electropho- 
resis (PFGE) and multilocus sequence typing (MLST). Percentage similarity at dendrogram analysis and sizes in kilobases (kb) of  λ DNA molecular  mass markers are indicated above the dendrogram and  PFGE proﬁles, respectively. 
Isolate  number,  date  of  isolation,  hospital/city,  source,  PFGE  type/subtype,  sequence  group  (G)  assigned  by  multiplex  PCR,  MLST,  international  clone  (IC)  or  clonal  complex  (CC)  by  SBT,  and  carbapenemase  genes  are  shown  on 
the  right  of  each  proﬁle.  VC,  venous  catheter;  CVC,  central  venous  catheter. 
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146 02.01.2015 General Hospital/Serres Urine A G1 ST2 IC2 OXA-23 
37 23.10.2015 AHEPAUniv. Hospital/Thessaloniki Trauma A G1 ST2 IC2 OXA-23 
68 05.01.2015 Tzaneio Hospital/Piraeus Blood A G1 ST2 IC2 OXA-23 
72 06.03.2015 Tzaneio Hospital/Piraeus VC A G1 ST2 IC2 OXA-23 
31 23.07.2015 AHEPAUniv. Hospital/Thessaloniki Tissue A1 G1 ST2 IC2 OXA-23 
40 09.05.2015 Univ. Hospital/Alexandroupolis PeritonealFluid A1 G1 ST2 IC2 OXA-23 
51 28.09.2015 Univ. Hospital/Ioannina Sputum A1 G1 ST2 IC2 OXA-23 
55 07.09.2015 Univ. Hospital/Ioannina Urine A1 G1 ST2 IC2 OXA-23 
147 08.01.2015 General Hospital/Serres Urine A2 G1 ST2 IC2 OXA-23 
69 28.01.2015 Tzaneio Hospital/Piraeus Rectal A3 G1ompA/blaoxa66 ST2 IC2 OXA-23 
153 30.07.2015 General Hospital/Serres Trauma A4 G1ompA/blaoxa66 ST2 IC2 OXA-23 
1 16.09.2015 Evaggelismos Hospital/Athens Blood B G1 ST2 IC2 OXA-23 
2 06.09.2015 Evaggelismos Hospital/Athens Blood B G1 ST2 IC2 OXA-23 
89 12.01.2015 Univ. Hospital/Heraklion Blood C G1 ST2 IC2 OXA-23 
189 16.07.2015 Eugenidio Hospital/Athens Sputum C1 G1 ST2 IC2 OXA-23 
197 13.11.2015 Iaso General Hospital/Larissa Urine C1 G1 ST2 IC2 OXA-23 
160 13.01.2015 G. Gennimatas Hospital/Athens Blood C2 G1csuE/G2ompA/blaoxa69 ST1 IC1 OXA-23 
159 20.01.2015 G. Gennimatas Hospital/Athens Blood C3 G1 ST2 IC2 OXA-23 
120 12.10.2015 KAT Hospital/Athens Pleural Fluid C4 G1 ST2 IC2 OXA-23 
134 02.04.2015 General Hospital/Serres Urine D G1 ST2 IC2 OXA-23 
20 16.01.2015 AHEPAUniv. Hospital/Thessaloniki CVC E G1csuE/G2ompA/blaoxa69 ST1 IC1 OXA-23 
21 16.01.2015 AHEPAUniv. Hospital/Thessaloniki Trauma E1 G2 ST1 IC1 OXA-58 
45 04.08.2015 Univ. Hospital/Alexandroupolis Blood E2 G1csuE/G2ompA/blaoxa69 ST1 IC1 OXA-23 
124 09.11.2015 KAT Hospital/Athens Blood F G6 ST78 CC78 OXA-40 
131 31.01.2015 General Hospital/Serres Bronchial G G2 ST1 IC1 OXA-23 
38 12.03.2015 Univ. Hospital/Alexandroupolis Blood G G2 ST1 IC1 OXA-23 
130 28.01.2015 General Hospital/Serres Blood G1 G2 ST1 IC1 OXA-23 
133 30.03.2015 General Hospital/Serres Blood G2 G2 ST1 IC1 OXA-23 
136 12.06.2015 General Hospital/Serres Bronchial G3 G1csuE/G2ompA/blaoxa69 ST1 IC1 OXA-23 
116 03.07.2015 KAT Hospital/Athens Blood G4 G2 ST1 IC1 OXA-23 
.166 16.02.2015 G. Gennimatas Hospital/Athens Blood G5 G2ompA/blaoxa69 ST1 IC1 OXA-23 
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Fig. 2. Geographical distribution of the identiﬁed oxacillinase genes and international clones (ICs) of the carbapenem-resistant Acinetobacter baumannii (CRAB) study iso- 
lates. Black dots indicate the location of hospitals in which the isolates were recovered (AL, Alexandroupolis; SE, Serres; TH, Thessaloniki; IO, Ioannina; LA, Larissa; AP, Athens/ 
Piraeus; HE, Heraklion). Coloured pie charts indicate the prevalence of different oxacillinases and ICs (in each region and in total). (For interpretation of the references to 
color in this ﬁgure legend, the reader is referred to the web version of this article.) 
 
 
A (with four subtypes), B, C (ﬁve subtypes) and D were found in 
ST2 isolates; and types E (three subtypes) and G (six subtypes) were 
found in ST1 isolates. The typing results of the 31 representative 
study isolates tested by all methods are shown in Fig. 1. 
The IC2 isolates were detected in all study hospitals and com- 
prised the vast majority of isolates (128/137; 93.4%) recovered from 
Western, Central and Southern Greece. The IC1 isolates were iden- 
tiﬁed in six hospitals; three of them were located in Northern Greece, 
where IC1 was quite common, including 49.1% of the 57 CRAB tested. 
Of the IC2 isolates, 154 had blaOXA-23-like and 3 had blaOXA-23-like plus 
blaOXA-58-like. As far as IC1 isolates, 34 had blaOXA-23-like  and 2 had 
blaOXA-58-like. The ST78 isolate harboured blaOXA-40-like. The geograph- 
ical distribution of the identiﬁed oxacillinase genes and ICs of the 
study isolates are shown in Fig. 2. 
Isolates belonging to IC1 were generally less resistant to anti- 
biotics compared with IC2. Important differences in the susceptibility 
rates between IC1 versus IC2 isolates were observed for minocycline 
(100%vs.65.0%), tetracycline(53.3%vs.1.3%)and tobramycin(65.2% 
vs. 16.4%). An opposite trend was observed for SXT, against which 
37.6% of IC2 isolates were susceptible compared with 13.9% for IC1 
isolates. 
 
4. Discussion 
 
Acinetobacter baumannii exhibits particularly high carbapenem 
resistance rates in several regions worldwide [22]. Of note, during 
2015 essentially no clinically important carbapenem-susceptible 
A. baumannii isolate has been recovered in the study Greek hospi- 
tals. The almost universal resistance to carbapenems and SAM 
precludes the use of β-lactams and considerably limits effective treat- 
ment options. Carbapenem resistance in A. baumannii is regularly 
due to the production of oxacillinases, the most frequent ones being 
OXA-23, OXA-40 and OXA-58 [5]. OXA-23 enzymes are recently in- 
creasing and tend to predominate among CRAB from distant regions 
worldwide [23], gradually replacing OXA-58 [7,8,24]. A similar ob- 
servation was made in the present nationwide study, with OXA- 
23 being by far the commonest enzyme detected, displacing 
OXA-58, which  was  the sole carbapenemase present until 2009 
among CRAB isolates throughout Greece [6]. It thus appears that 
the international shift towards OXA-23 predominance also applies 
to Greece. 
During the last few years, isolates belonging to IC2 have ex- 
panded particularly and currently include the majority of CRAB 
isolates worldwide [5,25]. In the current study, very few lineages 
were shown to circulate in Greece, with IC2 being the commonest 
lineage detected. A similar trend was also observed already in our 
previous nationwide study, which showed that after 2005 IC2 was 
more prevalent in Greece than IC1 [6]. 
Among the few antimicrobials that remained potent, alarm- 
ingly high resistance rates (27.3%) were observed for colistin. We 
should note that until recently colistin was considered almost con- 
sistently active against CRAB and is most commonly included in 
combination therapies of infections caused by CRAB [26]. Minocycline 
exhibited a considerable degree of activity (71.6%), as was also found 
in a recent worldwide surveillance report showing minocycline 
susceptibility rates of 66.2% and 62.9% against MDR and XDR 
A. baumannii, respectively [3]. Tigecycline was also shown to retain 
eﬃcient activity against the Greek CRAB isolates, with MIC50/90 values 
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Appendix 
 
The following members of the Greek Study Group on 
Acinetobacter Antimicrobial  Resistance   contributed   signiﬁcantly 
to the study design and strain collection: L. Skoura (AHEPA Uni- 
versity Hospital, Thessaloniki, Greece); K. Themeli-Digalaki (Tzaneio 
Hospital, Piraeus, Greece); E. Perivolioti (Evangelismos Hospital, 
Athens,  Greece);  S.  Tsiplakou  (KAT  Hospital,  Athens,  Greece); 
V. Karavassilis (IASO Hospital, Larissa, Greece); M. Panopoulou 
(University Hospital of Alexandroupolis, Alexandroupolis, Greece); 
M. Orfanidou (‘G. Gennimatas’ General Hospital, Athens, Greece); 
C. Hadjichristodoulou (Department of Hygiene and Epidemiology, 
Medical School, University of Thessaly, Larissa, Greece); S. Levidiotou 
(Department of Microbiology, Medical School, University of 
Ioannina, Ioannina, Greece); and A. Gikas (Department of Internal 
Medicine, Infectious Diseases Unit, University Hospital of Heraklion, 
Crete, Greece). 
 
References 
 
[1] Visca P, Seifert H, Towner KJ. Acinetobacter infection—an emerging threat  to 
human  health.  IUBMB  Life  2011;63:1048–54. 
[2] European Centre for Disease Prevention and Control. Antimicrobial resistance 
surveillance in Europe. Annual report of the European Antimicrobial Resistance 
Surveillance Network (EARS-Net) 2014. Stockholm, Sweden: ECDC;  2015. 
Available  from:   http://ecdc.europa.eu/en/publications/Publications/antimicrobial 
-resistance-europe-2014.pdf  [Accessed  12  April  2017]. 
[3] Flamm RK, Castanheira M, Streit JM, Jones RN. Minocycline activity tested against 
Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and 
Burkholderia cepacia species complex isolates from a global surveillance program 
(2013). Diagn Microbiol Infect Dis 2016;85:352–5. 
[4] Fishbain J, Peleg AY. Treatment of Acinetobacter infections. Clin Infect Dis 
2010;51:79–84. 
[5] Zarrilli R, Pournaras S, Giannouli M, Tsakris A. Global evolution of multidrug- 
resistant Acinetobacter baumannii clonal lineages. Int J Antimicrob Agents 
2013;41:11–19. 
[6] Gogou V, Pournaras S, Giannouli M, Voulgari E, Piperaki ET, Zarrilli R, et al. 
Evolution of multidrug-resistant Acinetobacter baumannii clonal lineages: 
an international expert proposal for interim standard deﬁnitions for acquired 
resistance. Clin Microbiol Infect 2012;18:268–81. 
[13] Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, et al. 
Multiplex PCR for genes encoding prevalent OXA carbapenemases in 
Acinetobacter spp. Int J Antimicrob Agents 2006;27:351–3. 
[14] Higgins PG, Lehmann M, Seifert H. Inclusion of OXA-143 primers in a multiplex 
polymerase chain reaction (PCR) for genes encoding prevalent OXA 
carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 2010;35:305. 
[15] Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of 
acquired carbapenemase genes. Diagn Microbiol Infect Dis 2011;70:119–23. 
[16] Turton JF, Ward ME, Woodford N, Kaufmann ME, Pike R, Livermore DM, et al. 
The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter 
baumannii. FEMS Microbiol Lett 2006;258:72–7. 
[17] Turton JF, Gabriel SN, Valderrey C, Kaufmann ME, Pitt TL. Use of sequence-based 
typing and multiplex PCR to identify clonal lineages of outbreak strains of 
Acinetobacter baumannii. Clin Microbiol Infect 2007;13:807–15. 
[18] Giannouli M, Cuccurullo S, Crivaro V, Di Popolo A, Bernardo M, Tomasone F, 
et al. Molecular epidemiology of multidrug-resistant Acinetobacter baumannii 
in a tertiary care hospital in Naples, Italy, shows the emergence of a novel 
epidemic clone. J Clin Microbiol 2010;48:1223–30. 
[19] Pournaras S, Gogou V, Giannouli M, Dimitroulia E, Dafopoulou K, Tsakris A, et al. 
Single-locus-sequence-based typing of blaOXA-51-like genes for rapid assignment 
of Acinetobacter baumannii clinical isolates to international clonal lineages. J 
Clin Microbiol 2014;52:1653–7. 
[20] Sahl JW, Del Franco M, Pournaras S, Colman RE, Karah N, Dijkshoorn L, et al. 
Phylogenetic and genomic diversity in isolates from the globally distributed 
Acinetobacter baumannii ST25 lineage. Sci Rep 2015;5:15188. 
[21] Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. 
Interpreting chromosomal DNA restriction patterns produced by pulsed-ﬁeld 
gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 
33:2233–9. 
[22] Lob SH, Hoban DJ, Sahm DF, Badal RE. Regional differences and trends in 
antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents 
2016;47:317–23. 
[23] Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide dissemination of the 
blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis 
2010;16:35–40. 
[24] Schleicher X, Higgins PG, Wisplinghoff H, Körber-Irrgang B, Kresken M, Seifert 
H. Molecular epidemiology of Acinetobacter baumannii and Acinetobacter 
nosocomialis in Germany over a 5-year period (2005–2009). Clin Microbiol Infect 
2013;19:737–42. 
[25] Karah N, Sundsfjord A, Towner K, Samuelsen Ø. Insights into the global 
molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter 
baumannii. Drug Resist Updat 2012;15:237–47. 
[26] Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant 
and extensively drug-resistant Acinetobacter baumannii infections. Drugs 
2014;74:1315–33. 
39 
Chapter 4 
Emergence of colistin resistance uncoupled from virulence attenuation after prolonged 
colistin administration in a patient with extensively drug-resistant Acinetobacter 
baumannii 
40  
Diagnostic Microbiology and Infectious Disease 82 (2015) 222–226 
 
 
 
 
 
 
 
Emergence of colistin resistance without loss of ﬁtness and virulence 
after prolonged colistin administration in a patient with extensively 
drug-resistant Acinetobacter baumannii 
Emanuele Durante-Mangoni a, Mariateresa Del Franco b, Roberto Andini a, Mariano Bernardo a, 
Maria Giannouli b, Raffaele Zarrilli b,⁎  
a 
Internal Medicine, University of Naples S.U.N. & AORN dei Colli, Monaldi Hospital, Via L. Bianchi, Naples, Italy 
b Department of Public Health, University of Naples “Federico II”, Naples, Italy 
 
 
a r t i c l e i n f o 
 
 
Article history: 
Received 26 November 2014 
Received in revised form 16 March 2015 
Accepted 18 March 2015 
Available online 25 March 2015 
 
 
Keywords: 
Acinetobacter  baumannii 
Colistintherapy  
Colistin resistance 
pmrB mutation 
In vitro ﬁtness 
In vivo virulence 
a b s t r a c t 
 
 
The spread of extensively drug-resistant (XDR) gram-negative bacteria has boosted colistin use, with a resultant 
selection of colistin-resistant, often pandrug-resistant  strains. Whether  acquisition of further resistance 
mechanisms translates into a reduced virulence is the subject of active research. In this report, we describe 
clinical features of an immunocompromised patient who developed infection due to colistin-resistant 
Acinetobacter baumannii while on long-term colistin therapy. We analyzed phenotypic and genotypic character- 
istics, molecular mechanisms of colistin resistance, and in vitro and in vivo ﬁtness of sequential colistin-sensitive 
and colistin-resistant strains isolated from the patient. Both colistin-sensitive and colistin-resistant strains were 
XDR and showed identical ST78 genotype. At variance with prior reports on colistin-resistant strains of 
A. baumannii, resistance to colistin due to P233S mutation in PmrB sensor kinase did not associate with any 
measurable reduction in strain ﬁtness, growth characteristics, and virulence. 
© 2015 Elsevier Inc. All rights reserved. 
 
 
 
 
1. Introduction 
 
Extensively drug-resistant (XDR) A. baumannii is increasingly 
responsible for healthcare-associated infections (Zarrilli et al., 2013). 
These infections are difﬁcult to treat, and a colistin-based regimen may 
represent the only available therapeutic option (Durante-Mangoni et al., 
2014). The emergence of colistin resistance in XDR A. baumannii has 
been reported as a consequence of prolonged exposure to this drug 
(Lesho et al., 2013; Pournaras et al., 2014; Snitkin et al., 2013). 
Two major mechanisms have been implicated in the development of 
resistance to colistin in A. baumannii. Mutations in the PmrA/B 2- 
component regulator, involved in the addition of phosphoethanolamine 
to hepta acylated lipid A, can lead to lipopolysaccharide (LPS) modiﬁca- 
tions (Adams et al., 2009; Beceiro et al., 2011; Lesho et al., 2013; Lopez- 
Rojas et al., 2011; Pournaras et al., 2014; Snitkin et al., 2013). Changes 
within either lpxA, lpxC, or lpxD lipid A biosynthesis pathway genes 
may in contrast result in the complete loss of the lipid A component of 
lipopolysaccharide (Moffatt et al., 2010). Mounting evidence indicates 
that colistin resistance in A. baumannii is associated with genomic insta- 
bility, high ﬁtness costs, and virulence attenuation (Beceiro et al., 2014; 
Lopez-Rojas et al., 2011; Pournaras et al., 2014; Snitkin et al., 2013). 
Aims of the present study were to analyze the mechanisms of colistin 
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resistance, the in vitro ﬁtness, and the virulence of consecutive 
colistin-susceptible (colistin-S) and colistin-resistant (colistin-R) 
A. baumannii strains isolated during colistin treatment from a single 
patient. 
 
2. Materials and methods 
 
2.1. Study design 
 
This was a clinical-microbiological case study aimed at investigating 
the relationship between loss of susceptibility to colistin and virulence 
phenotypes in strains of A. baumannii. Colistin-R strains were grown 
from a single patient previously screened under informed consent for 
participation in the CoRAb trial (Durante-Mangoni et al., 2013) and 
not randomized due to lack of fulﬁllment of inclusion criteria. In this 
trial, inclusion criteria were age ≥18 years and microbiological evidence 
of a life-threatening pneumonia or bloodstream or intra-abdominal in- 
fection due to XDR A. baumannii susceptible to colistin, while exclusion 
criteria were previous treatment with or hypersensitivity to colistin. The 
index   patient   was   initially   deemed   colonized   not   infected   by 
A. baumannii. The study protocol had been approved by the Ethics Com- 
mittee of the Monaldi Hospital. Patient's chart was evaluated, and rele- 
vant clinical data were collected after strain isolation. These included 
detailed antibiotic treatment regimens, prospective microbiology data, 
as well as clinical course. 
 
http://dx.doi.org/10.1016/j.diagmicrobio.2015.03.013 
0732-8893/© 2015 Elsevier Inc. All rights reserved. 
Contents lists available at ScienceDirect 
 
Diagnostic Microbiology and Infectious Disease 
 
journal   homepage:   www.elsevier.com/ locate/ diagmicrobio 
41  
Table 1 
Epidemiological, phenotypic, and genotypic features of A. baumannii strains. 
 
Strain Year/country Specimen    blaOXA genes    PFGE 
type 
 
MLST   MIC (μg/mL) 
of antibiotic 
 
Mechanism of 
colistin resistance 
 
Colistin (dose/route) 
at time of isolate growth 
 
Reference 
 
     ST IPM MEM TIG COL    
Ab4450a 07/06/2010/NA/IT BA blaOXA-58, A 78 32 16 4 0.5 None None Unpublished 
 
Ab4451a 
 
26/08/2010/NA/IT 
 
BA 
blaOXA-64 
blaOXA-58, 
 
A1 
 
78 
 
8 
 
8 
 
2 
 
128 
 
pmrB mutation 
 
2 MU tid IV 
 
Unpublished 
 
Ab4452a 
 
26/08/2010/NA/IT 
 
BA 
blaOXA-64 
blaOXA-58, 
 
A1 
 
78 
 
64 
 
8 
 
2 
 
128 
P233S 
pmrB mutation 
 
2 MU tid IV 
 
Unpublished 
 
Ab4453a 
 
28/10/2010/NA/IT 
 
BA 
blaOXA-64 
blaOXA-58, 
 
A2 
 
78 
 
32 
 
8 
 
2 
 
0.5 
P233S 
None 
 
None 
 
Unpublished 
blaOXA-64 
3909 05/11/2007/IT BA blaOXA-58, A 78 32 8 2 0.5 None None (Giannouli et al., 2010; 
 
ATCC19606T 
 
Before 1949/AT/USA 
 
UC 
blaOXA-64 
blaOXA-98 
 
B 
 
52 
 
2 
 
2 
 
1 
 
0.5 
 
None 
 
Not applicable 
Zarrilli et al., 2011) 
(Janssen et al., 1997) 
Abbreviations: NA = Napoli; IT = Italy; AT = Atlanta; BA = bronchial aspirate; UC = urine culture; ST = sequence type; IPM = imipenem; MEM = meropenem; TIG = tigecycline; 
COL = colistin; MU = million units. 
a   A. baumannii strains isolated from the same patient. 
 
2.2. Bacterial strain identiﬁcation and genotyping 
 
Bacterial strains included in the study are listed in Table 1. Strain 
identiﬁcation of A. baumannii isolates was performed, as previously 
described (Giannouli et al., 2010). Genotyping was performed by ApaI 
DNA macrorestriction, pulsed-ﬁeld gel electrophoresis (PFGE), and 
dendogram analysis and multilocus sequencing typing (MLST) analysis, 
as previously described (Giannouli et al., 2010). Interpretation of 
genetic relatedness of PFGE proﬁles was performed using the criteria 
of Tenover et al. (1995). 
 
2.3. Antimicrobial susceptibility testing 
 
Susceptibility testing of all antimicrobials was performed using the 
VITEK 2 system and the AST-GN089 card (bioMérieuxMarcy l’Étoile, 
France). Colistin susceptibility was evaluated by broth microdilution in 
Mueller–Hinton broth II (MHBII) according to Clinical and Laboratory 
Standards Institute guidelines (CLSI, 2010) using untreated polystyrene 
microplates. Colistin susceptibility of the 4 A. baumannii strains included 
in the study was conﬁrmed by broth macrodilution in MHBII using boro- 
silicate tubes, which was recently shown to exhibit excellent performance 
for colistin MIC testing of multidrug-resistant A. baumannii isolates 
(Pournaras et al., 2014). Tigecycline MIC results were interpreted accord- 
ing to the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) criteria (susceptible, ≤1 μg/mL; and resistant, ≥4 μg/mL) 
(EUCAST Steering Committee, 2006). In the absence of internationally 
recognized breakpoints, A. baumannii resistance to rifampicin was deﬁned 
as an MIC N16 μg/mL according to the recommendations of the French So- 
ciety of Microbiology (Bonnet et al., 2013). Multidrug-resistant and XDR 
phenotypes were deﬁned according to Magiorakos et al. (2012). 
 
2.4. PCR and sequencing 
 
PCRs for the blaOXA-51–like, blaOXA-58–like, blaOXA-23–like, 
blaOXA-24–like, blaVIM, blaIMP, blaSIM, pmrA, pmrB, pmrC, lpxA, lpxC, 
and lpxD genes were performed as described previously (Giannouli 
et al., 2010; Pournaras et al., 2014). Nucleotide sequences obtained 
were compared with the deduced amino acid sequence available in 
GenBankusingBasicLocalAlignmentSearchToolsoftware. 
 
2.5. Bacterial viability 
 
A logarithmic-phase culture of each strain was adjusted to ca. 
106 CFU/mL in MHBII. Five-milliliter cultures in glass tubes were incu- 
bated in a shaking water bath at 37 °C, and viable bacteria were counted 
after 0, 4, 8, 16, 24 and 48 h. At each time, after vortexing, a 0.5-mL sam- 
ple was removed from the cultures, and serial 10-fold dilutions were 
made in MHBII. Bacterial viability was measured by pour-plating 25-
μL aliquots of the appropriate dilution in MHBII onto 5% sheep 
blood agar plates (Oxoid SpA, Garbagnate Milanese, Italy) in duplicate 
and incubating for 24 h at 37 °C. All experiments were repeated 3 
times. Differences in bacterial viability were calculated by the general- 
ized linear model for multivariate comparisons. Differences were 
considered statistically signiﬁcant at P b 0.05. 
 
2.6. Galleria mellonella killing assay 
 
The  virulence  of  A.  baumannii  in  vivo  was  assessed  using  the 
G.   mellonella   insect   model   of   infection,   as   previously   described 
(Giannouli et al., 2013). Survival curves were plotted using the Kaplan– 
Meier method, and differences in survival were calculated using the log- 
rank  test   for  multiple  comparisons.  Differences  were  considered 
statistically signiﬁcant at P b 0.05. Lethal dose 50% (LD50) values were 
calculated using GraphPad Prism v.5.04 (GraphPad Software, La Jolla, 
CA, USA), as previously described (Giannouli et al., 2013). All experiments 
were  performed  at  least  3  times,  and  the  results  were  shown    as 
means  ±   SEM.  Differences  between  mean  values  were  tested  for 
signiﬁcance by performing 1-way analysis of variance followed by Tukey's 
multiple-comparison  test.  A  P  value  b0.05  was  considered  to  be 
statistically signiﬁcant. 
 
3. Results 
 
3.1. Selection of colistin-R A. baumannii during colistin therapy 
 
A 66-year-old woman was admitted to the Monaldi Hospital 
because of ischemic heart disease. On May 21, 2010, the patient 
underwent coronary artery bypass grafting complicated by severe 
biventricular failure. After extracorporeal cell membrane oxygenation 
device placement, as no functional recovery occurred, the patient was 
waitlisted for heart transplant. All surveillance cultures from blood, 
tracheal aspirate, surgical sites, and rectum were negative for sentinel 
microorganisms. On May 27, 2010, the patient received an AB0 
compatible graft and was started on a standard immunosuppressive 
regimen including antithymocyte globulins, polyclonal immune 
globulins, high-dose metilpredisolone followed by cyclosporin A and 
micophenolate mofetil. Both surgeries were performed under 48 h 
prophylaxis with amoxicillin-clavulanic acid, 2.2 g thrice in a day (tid). 
Despite an uneventful transplantation procedure, the subsequent 
course was complicated by kidney failure requiring renal replacement 
therapy and prolonged intubation followed by tracheostomy. Antifun- 
gal prophylaxis with ﬂuconazole was given for 6 days. Because of a 
pulmonary inﬁltrate on chest x-ray, meropenem 1 g tid intravenously 
(IV) was started. On June 7, a bronchial aspirate showed the presence 
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of 106 CFU/mL of XDR A. baumannii, i.e., nonsusceptible to all 
antimicrobial classes but susceptible to tigecycline and colistin 
(Magiorakos et al., 2012). Antimicrobial susceptibility studies showed 
MICs for meropenem and colistin of 16 and 0.5 μg/mL, respectively. 
Nebulized colistin methanesulphonate was started at the dose of 1 
MU tid on June 9 for 7 days, and a tracheostomy was performed. 
Follow-up airway cultures repeatedly obtained from June 14 on showed 
the persistence of XDR-A. baumannii with the same antibiotype. This 
condition was deemed as airways colonization, and no further colistin 
was given. Patient clinical conditions only moderately improved, 
allowing withdrawal of all sedatives, but renal function remained 
signiﬁcantly compromised with an estimated glomerular ﬁltration rate 
below 30 mL/min. Multiple other microbial pathogens were isolated, 
including Staphylococcus epidermidis and Enterococcus faecium from 
blood, and MRSA repeatedly from bronchial aspirates, requiring 
treatment with vancomycin and, subsequently, linezolid. One month 
after transplant, KPC-producing Klebsiella pneumoniae was isolated 
from blood, lung, and urine cultures. Intravenous colistin, 2 MU q8h, 
was started and continued for 45 days. During this period and under 
this regimen, cultures from removed central venous catheter tips and 
airways remained persistently positive for XDR A. baumannii with 
MICs for colistin and tigecycline equal to 0.5 and 2 μg/mL. 
On August 26, colistin-R A. baumannii strains were grown for the ﬁrst 
time from 2 subsequent bronchial aspirates. These strains showed 
colistin MICs of 128 μg/mL and were also resistant to all beta-lactams, 
imipenem and meropenem carbapenems, aminoglycosides, and 
trimethoprim/sulfamethoxazole, but not tigecycline. Colistin was with- 
drawn, and no other antimicrobial active against gram-negative bacilli 
was given. Ten days later, another XDR-Acb strain was isolated in a 
bronchial aspirate, showing again a colistin MIC of 0.5 μg/mL. No further 
colistin was given, and all subsequent XDR-Acb strains showed an MIC 
ranging from 0.5 to 1 μg/mL. Tigecycline was started instead at the 
dose of 100 mg bid i.v. after a 200 mg loading dose. XDR-A. baumannii 
persisted also during this course, showing unchanged colistin MIC 
equal to 0.5 μg/mL. In the following days, patient conditions progres- 
sively deteriorated with development of multiorgan failure. Since 
September 2010, other infections supervened such as Stenotrophomonas 
maltophilia pneumonia and candidemia. Multiple colonizing 
microorganisms were also grown, including extended-spectrum beta- 
lactamase–producing Escherichia coli,  methicillin-resistant  Staphylococ- 
cus aureus and S. epidermidis, and Enterococcus faecalis. The patient 
eventually died on October 31, 2010. 
 
3.2. Phenotypic and genotypic characterization of A. baumannii strains 
 
All 4 A. baumannii strains isolated from the patient available were 
included in the analysis. Their phenotypic and genotypic characteristics 
are reported in Table 1. A. baumannii strain Ab4450 was isolated on June 
7, before initiation of colistin treatment, and showed susceptibility to 
colistin (MIC 0.5 μg/mL). A. baumannii strains Ab4451 and Ab4452 
were isolated on August 26, during colistin therapy, from 2 different 
samples of bronchial aspirate, and showed  resistance  to  colistin 
(MIC 128 μg/mL). A. baumannii strain Ab4453 was isolated on October 
28, 8 weeks after discontinuation of colistin therapy, and showed 
susceptibility to colistin (MIC 0.5 μg/mL). All 4 A. baumannii strains 
were XDR, i.e., nonsusceptible to at least 1 agent in all antimicrobial 
classes including carbapenems  (imipenem  MICs  ranging  from  8  to 
64 μg/mL; meropenem MICs ranging from 8 to 16 μg/mL), intermedi- 
ate/susceptible to tigecycline (MICs ranging from 2 to 4 μg/mL), and 
susceptible to rifampin (MICs ranging from 2 to 4 μg/mL). Molecular 
typing by PFGE assigned the 4 A. baumannii strains isolated from the 
patient to the same PFGE type, which we named A. PFGE type A could 
be further classiﬁed into subtypes A1 and A2, which differed in the 
migration of 3 bands from PFGE type A, respectively. The colistin-S 
strain Ab4450 showed identical PFGE proﬁle (type A) to that of the 
epidemic A. baumannii strain 3909 isolated in the Monaldi Hospital in 
2007 (Giannouli et al., 2010). The 2 colistin-R strains Ab4451 and 
Ab4452 showed identical PFGE proﬁle A1, whereas the colistin-S strain 
Ab4453 isolated after colistin withdrawal was assigned to PFGE type A2 
(Fig. 1 and Table 1). In particular, the 2 colistin-R strains assigned to 
PFGE type A1 showed a new larger fragment of 400 kb, and the absence 
of 2 smaller fragments of 190 and 230 kb compared to the colistin-S ini- 
tial strain Ab4450 isolated from the patient assigned to PFGE type A, 
thus suggesting that a single genetic event might have caused the loss 
of a restriction site. A. baumannii colistin-S strain isolated after colistin 
therapy withdrawal showed a PFGE proﬁle distinct from both types A 
and A1 and was assigned to PFGE type A2 (Fig. 1 and Table 1). All 4 
A. baumannii strains Ab4450, Ab4451, Ab4452, and Ab4453 were 
assigned through Institute Pasteur's MLST typing scheme to ST78 epi- 
demic clonal lineage (Giannouli et al., 2010). PCR and sequence analysis 
identiﬁed expression of a blaOXA-58 gene, which confers resistance to 
carbapenems,  and  a  naturally  occurring  blaOXA-64  gene  in  all 
A. baumannii strains analyzed. Compared with colistin-S strains 
Ab4450, Ab4453, and 3909 (Zarrilli et al., 2011), colistin-R strains 
Ab4451 and Ab4452 harbored the amino acid substitution P233S in 
the PmrB sensor kinase of PmrAB 2-component system, which has 
been described as an activating mutation in colistin-R A. baumannii 
strains (Pournaras et al., 2014; Snitkin et al., 2013). No mutations 
were detected in genes pmrA and pmrC, coding for the response 
regulator and the lipid A phosphoethanolamine transferase of the 
PmrCAB operon, respectively. Likewise, there were no changes in lipid 
A biosynthesis pathway genes lpxA, lpxC, and lpxD in any of the analyzed 
A. baumannii strains (Table 1). 
We also investigated the in vitro and in vivo ﬁtness of the 2 colistin-R 
A. baumannii strains and compared it with that of colistin-S strains, 
including ATCC19606 reference strain (Table 1). The growth curves of 
colistin-R strains Ab4451 and Ab4452 showed no signiﬁcant differences 
compared with colistin-S strains Ab4450, Ab4453, and ATCC19606 
(P = 0.548 for multivariate comparisons by the generalized linear 
model) (Fig. 2). Consistently, there were no statistical signiﬁcant 
differences of LD50 values in a G. mellonella killing assay among 
A. baumannii colistin-R strains Ab4451 and Ab4452 and colistin-S 
strains Ab4450, Ab4453, and ATCC19606 at any time postinfection 
(P = 0.486, P = 0.0.483, and P = 0.0692 at 24, 48, and 72 h, respectively, 
for multiple comparison test) (Table 2). 
 
4. Discussion 
 
In the last decade, colistin has become the last resource antibiotic for 
infections due to gram-negative rods resistant to carbapenems as well 
as multiple other classes of drugs. The spread of these pathogens across 
hospitals has translated into an exponential increase in the use of 
colistin, especially in intensive care units. Despite an inherently low 
barrier toward resistance, growing colistin utilization is posing the 
bases for the emergence of nonsusceptible strains. 
This has occurred infrequently to date and has been coupled to a 
sharp reduction in ﬁtness and virulence of A. baumannii strains 
(Beceiro et al., 2014; Lopez-Rojas et al., 2011; Pournaras et al., 2014; 
Snitkin et al., 2013). However, different mechanisms of colistin 
resistance might have a different impact on ﬁtness and virulence. A 
more pronounced biological cost was observed in isolates lacking LPS 
(Beceiro et al., 2014) compared to those with phosphoethanolamine 
addition to LPS mediated through mutations in pmrB (Lopez-Rojas 
et al., 2011; Pournaras et al., 2014; Snitkin et al., 2013). 
In this report, we describe the genotypic and phenotypic character- 
istics of 2 colistin-S and 2 colistin-R A. baumannii strains isolated from a 
single patient who developed in vivo resistance to colistin after 
prolonged exposure to the drug. We hypothesize that the persistence 
of XDR A. baumannii in the airways, coupled with a short course of in- 
haled colistin and a longer administration of intravenous colistin with 
little epithelial lining ﬂuid penetration, favored sub-MIC concentrations 
of this drug at the infection site, leading to selection of colistin-R strains. 
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Fig. 1. Genotypic analysis of digitized ApaI PFGE proﬁles of A. baumannii strains included in the study. Strain numbers, PFGE proﬁles, and colistin susceptibility are shown. Percentage of 
similarity at dendogram analysis and position and tolerance values of the DICE correlation coefﬁcient used in clustering are also shown. 
 
In accordance with previous data (Snitkin et al., 2013), a strain suscep- 
tible to colistin outcompeted resistant strains upon colistin withdrawal. 
The reversion of colistin resistance in A. baumannii may occur through 
clonal replacement by an ancestral susceptible strain or by a compensa- 
tory inactivating mutation (Snitkin et al., 2013). Our data indicate that 
both susceptible and resistant A. baumannii strains belonged to the 
same major PFGE proﬁle A but showed distinct PFGE subtypes A, A1, 
and A2. The above data suggest also that colistin-R strains of PFGE 
type A1 originated from the colistin-S strain of PFGE type A initially 
isolated from the patient because of at least 1 genetic mutation 
occurring in vivo during colistin therapy. A subsequent genetic 
mutation might have been responsible for the evolution, under further 
selection pressures, of the PFGE type A2 colistin-S strain, which 
outcompeted  resistant  isolates  upon   colistin   withdrawal.   All   4 
A. baumannii strains belonged to ST78 epidemic clonal lineage, which 
emerged recently in Italy (Giannouli et al., 2010; Zarrilli et al., 2013). 
In prior reports, colistin-R A. baumannii strains isolated during patient 
treatment belonged to either international clonal lineage II 
(Pournaras et al., 2014; Snitkin et al., 2013) or international clonal line- 
age I (Snitkin et al., 2013) or to nonepidemic ST94  genotype 
(Lesho et al., 2013), suggesting that colistin resistance may develop in 
different genetic backgrounds. In accordance with previous data 
(Pournaras  et  al.,  2014;  Snitkin  et  al.,  2013),  the  2  resistant 
A. baumannii strains showed an identical point mutation in pmrB that 
generated the single amino acid substitution P233S in the PmrB sensor 
kinase of PmrAB 2-component system. No other nucleotide changes 
were detected in pmrCAB locus or lpxA, lpxC, and lpxD lipid A biosynthe- 
sis pathway genes. The absence of other nucleotide changes in pmrCAB 
locus excludes the possibility that reversion of the resistance phenotype 
was contributed by a compensatory inactivating mutation, as reported 
previously in A. baumannii (Snitkin et al., 2013). At variance with prior 
reports in A. baumannii colistin-R strains (Lopez-Rojas et al., 2011; 
Pournaras et al., 2014; Snitkin et al., 2013), pmrB mutation detected by 
us did not induce any measurable change in strain growth rate as well 
as no attenuation of lethality in a G. mellonella killing assay, suggesting 
 
  
 
 
 
Fig. 2. Growth curves of the study and control isolates. y axis, CFU/mL from broth cultures: 
x axis, time of growth (hours). 
that virulence attenuation paralleling resistance development might 
be dependent on additional unidentiﬁed genetic factors that may differ 
among A. baumannii strains and/or genotypes. Conversely, the data 
shown herein are in partial agreement with a recent study showing 
that colistin resistance in A. baumannii ATCC19606 due to mutation in 
pmrB has less impact on ﬁtness and virulence than colistin resistance 
in A. baumannii ATCC19606 lpxA, lpxC, and lpxD isogenic mutants, 
showing complete loss of lipopolysaccharide (Beceiro et al., 2014). In 
agreement with our data, colistin resistance due to PmrB sensor kinase 
mutation was not associated with signiﬁcant ﬁtness costs in KPC- 
producing Klebsiella pneumoniae strains isolated during colistin 
treatment (Cannatelli et al., 2014). 
There are some possible clinical drivers of the dynamics of colistin 
susceptibility in this case. The patient was a severely immunocompro- 
mised organ transplant recipient, who underwent 2 subsequent major 
surgeries with serial cardiac and renal dysfunction. Colistin had been 
administered initially nebulized via aerosol, subsequently intravenous- 
ly, and with a possibly inadequate posology to reach inhibitory concen- 
trations within the airways. These factors have likely contributed to 
emergence of colistin resistance in lung isolates. Following withdrawal 
of this drug, the P233S substitution-carrying strains disappeared. 
Based on the above data, we hypothesize that the selective pressure 
exerted by colistin was required for colistin resistance to emerge; on 
the other hand, despite conserved ﬁtness and virulence, the pmrB mu- 
tant still had a disadvantage underlying its disappearance following co- 
listin withdrawal. 
 
 
5. Conclusions 
 
We described the emergence of a colistin-R strain in an immuno- 
compromised patient treated with a short course of inhaled colistin 
and a longer administration of relatively low doses of intravenous colis- 
tin. The mutation underlying colistin resistance involved the PmrB 
sensor kinase of PmrAB 2-component system and did not translate 
into an in vitro measurable reduction of growth capacity or virulence. 
However, withdrawal of colistin was followed by disappearance of the 
 
 
Table 2 
Lethal dose 50% of A. baumannii strains in G. mellonella. 
 
Strains LD50   
 24 h 48 h 72 h 
4450 9.4 (±0.4) × 106 8.6 (±0.4) × 10
6
 8.0 (±0.4) × 106 
4451 7.0 (±0.6) × 10
6
 1.5 (±0.2) × 106 1.1 (±0.3) × 106 
4452 1.0 (±0.2) × 10
7
 5.5 (±0.8) × 106 1.2 (±0.4) × 106 
4453 
ATCC19606T 
6.5 (±0.6) × 106 
8.0 (±0.7) × 106 
3.5 (±0.2) × 106 
5.6 (±0.3) × 106 
2.4 (±0.3) × 106 
4.0 (±0.2) × 106 
The LD50  values  are expressed in CFUs. Values  represent the mean (±SEM)  of  3 
independent experiments. 
44 
resistant strain. We provide further evidence that selection of colistin 
resistance in XDR A. baumannii may be dependent on different molecu- 
lar mechanisms and is not invariably associated with virulence 
attenuation. 
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Background 
Acinetobacter baumannii is a Gram-negative pathogen 
associated with multidrug resistance and hospital out- 
breaks of infection, particularly in the intensive care unit 
[1]. A. baumannii accounts for almost 80 % of all reported 
Acinetobacter infections, including ventilator-associated 
pneumonia, bacteremia, meningitis, peritonitis, urinary 
tract infections, and wound infections [1]. The rapid 
emergence of multidrug-resistant A. baumannii strains 
has resulted in limited treatment options, with most 
strains being resistant to clinically useful antibiotics [2]. A. 
baumannii cells readily form biofilms in vitro [3–5], and 
the ability of nosocomial strains to form biofilms on 
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medical devices as in host tissues represents an important 
factor of microbial virulence. Cells forming biofilms are 
embedded within a polymeric conglomerate of proteins 
and polysaccharides. Biofilms are resistant to host im- 
mune defenses, detergents and antibiotics, and antibiotic 
resistance of microrganisms in these habitats can be in- 
creased up to a thousand-fold [6]. 
As in other microrganisms [7, 8] also in A. baumannii 
the formation of biofilm is a redundantly organized, 
multifactorial process involving multiple cellular compo- 
nents. The initial cell attachment to a surface is plausibly 
mediated by pili-like structures encoded by the csu locus 
[9], which are widespread among clinical isolates. However, 
the strong biofilm producer ATCC10696 strain lacks 
csu-encoded pili, as the ATCC17978 strain which expresses 
a different type of pili [10, 11]. Biofilms eventually grow 
by production of poly-beta-(1–6)-N-acetylglucosamine 
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Abstract 
Background: A giant protein called BAP (biofilm-associated protein) plays a role in biofilm formation and adhesion 
to host cells in A. baumannii. Most of the protein is made by arrays of 80–110 aa modules featuring 
immunoglobulin-like (Ig-like) motifs. 
Results: The survey of 541 A. baumannii sequenced strains belonging to 108 STs (sequence types) revealed that   
BAP  is  highly  polymorphic,  distinguishable  in  three  main  types  for  changes  both  in  the  repetitive  and  the  COOH 
region. Analyzing the different STs, we found that 29 % feature type-1, 40 % type-2 BAP, 11 % type-3 BAP, 20 % lack 
BAP. The type-3 variant is restricted to A. baumannii, type-1 and type-2 BAP have been identified also in other 
species of the Acinetobacter calcoaceticus-baumannii (ACB) complex. A. calcoaceticus and A. pittii also encode 
BAP-like proteins in which Ig-like repeats are replaced by long tracts of alternating serine and aspartic acid residues. 
We have identified in species of the ACB complex two additional proteins, BLP1 and BLP2 (BAP-like proteins 1 and 
2) which feature Ig-like repeats, share with BAP a sequence motif at the NH2 terminus, and are similarly expressed   
in stationary growth phase. The knock-out of either BLP1 or BLP2 genes of the A. baumannii ST1 AYE strain severely 
affected  biofilm  formation,  as  measured  by  comparing  biofilm  biomass  and  thickness,  and  adherence  to  epithelial 
cells. BLP1 is missing in the majority of type-3 BAP strains. BLP2 is largely conserved, but is frequently missing in 
BAP-negative cells. 
Conclusions: Multiple proteins sharing Ig-like repeats seem to be involved in biofilm formation. The uneven 
distribution of the different BAP types, BLP1, and BLP2 is highly indicative that alternative protein complexes 
involved in biofilm formation are assembled in different A. baumannii strains. 
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controlled by the pga locus [12]. The extracellular 
matrix provides adhesion between bacterial cells, enab- 
ling the formation of a multilayered structure. Several 
surface proteins are also involved in the process, and 
appear to differently contribute to the attachment of 
cells tobiotic or abiotic surfaces. The major outer mem- 
brane protein OmpA is essential for the attachment of 
A. baumannii to human alveolar epithelial cells, but 
plays a role also in the development of biofilms on plas- 
tic [13]. In contrast, both cell adhesiveness and biofilm 
formation are high in A. baumannii isolates expressing 
the PER-1 extended-spectrum beta-lactamase [14]. 
Inactivation of a protein called BAP (for biofilm- 
associated protein) in the ST (sequence type) 1 AB307- 
0294 strain resulted both in decreased biofilm growth on 
glass [15] and decreased adherence to human bronchial 
cells [16]. BAP is expressed at the cell surface, and bio- 
film formation by BAP-positive strains is inhibited by 
affinity-purified BAP antibodies [17]. BAPs are large 
multidomain proteins playing a role in the process of 
biofilm formation both in Gram-negative and Gram- 
positive bacteria [18, 19]. These proteins exhibit poor se- 
quence similarity, but share structural similarities, as 
they are internally repetitious and feature multiple (3 to 
50 copies) immunoglobulin-like domains. These domains 
have a peculiar three-dimensional structure known as Ig 
fold, composed of 70–100 amino acid (aa) residues in 
seven anti-parallel beta-strands organized in two beta- 
sheets packed against each other in a sandwich structure 
[18]. In S. epidermidis, the Embp (extracellular matrix- 
binding protein) protein, involved both in cell adherence 
and biofilm formation [20], is enriched in modules differ- 
ent from Ig-fold repeats called FIVAR (Found In Various 
Architectures, 59 copies) and GA (G-related albumin- 
binding, 38 copies). 
In different species, BAP genes are accessory genome 
components. The E. faecalis BAP gene is inserted in a 
153 Kb pathogenicity island, the S. aureus BAP gene in a 
composite transposon comprising an ABC transporter 
operon and a transposase, in turn inserted in the 27 kb 
mobile pathogenicity island SaPIbov2 [21]. The gene was 
identified in 5 % of the S. aureus bovine mastitis, but in 
none of the human S. aureus isolates studied [22]. S. epi- 
dermidis isolates from animal mastitis forming biofilms 
possess a gene highly homologous to the S. aureus BAP 
gene, but not other SaPIbov2 sequences. Similarly, the 
Bhp (Bap homologue protein) protein is present only in 
some human S. epidermidis biofilm producers, as the 
RP62A strain [23]. 
In contrast, the BAP gene is largely conserved in the 
A. baumannii population, having been identified in iso- 
lates belonging to different STs [15]. Differently from 
other species, in A. baumannii the BAP gene is unlinked 
togenes involved inprotein secretion. The BAP detected 
in A. baumannii ST92 isolates is approximately four 
times smaller than the AB307-0294 protein [17]. Size 
heterogeneity plausibly denotes changes in the number 
of protein repeats due to recA-independent slipped- 
strand mispairing during DNA replication, as reported 
for S. aureus BAP variants[24]. 
In this work, we have studied the organization of BAP 
coding sequences in wholly sequenced strains as in a large 
set of whole genome shotguns (WGS) of both A. bauman- 
nii (Additional file 1) and other Acinetobacter species. In 
silico analyses had been carried out also for two surface 
proteins, that we have called BLP1 and BLP2 (for BAP- 
like proteins) structurally related to BAP because similarly 
containing Ig-like domains. We showed that A. bauman- 
nii BAPs come in different formats, for changes in the 
number and type of repeats, and organization of the 
COOH region. Data mining suggest functional hierarchy 
linking BAP to BLPs, a hypothesis strengthened by the ob- 
servation that gene disruption of either BLP gene impaired 
biofilm formation and adhesiveness to epithelial cells. 
 
Results 
Heterogeneity  of  BAP  proteins  among  A.  baumannii 
strains 
The BAP protein identified in the A. baumannii strain 
AB307-0294 contains 8621 aa, and features seven dis- 
tinct repeat units ranging in size from 70 to 104 aa. Re- 
peats A-D exhibit poor similarity to each other, but all 
share Big_3_4 (Bacterial Ig-like domain, group 3) motifs, 
fitting the consensus TDnAGN, found in many bacterial 
surface proteins (PFAM accession n. PF13754). B, C and 
D repeats are over-represented, and account for 2/3 of 
the AB307-0294 BAP. Repeats E, F and G lack Big_3_4 
motifs, and are reiterated in tandem in the COOH re- 
gion. A third G-like repeat is located downstream at 
170 aa distance. A-G repeat sequences are reported 
in Additional file 2. 
In BAP proteins found in wholly-sequenced A. bau- 
mannii genomes (Fig. 1), the NH2 region is conserved, 
the COOH region varies in length because either 2 or 4 
copies of the EFG module are present (Additional file 2). 
Small and large COOH regions, which exhibit 44 % se- 
quence identity, mark BAPs encoded by strains belong- 
ing to the abundant sequence types ST1 and ST2, which 
correspond to international clone I and II, respectively 
[25]. Accordingly, the corresponding proteins have been 
classified as type-1 and type-2 BAPs. Length and com- 
position of the central repetitive region is also variable. 
According to GenBank annotations, intact BAPs are 
encoded by the AYE (8200 aa) and BJAB0715 (3059 aa) 
strains only, while the 8621 aa AB307-0294 protein de- 
scribed by Loehfelm and coworkers [15] is split in ORFs 
776 and 777. The discrepancy may either signal that a 
mutation occurred in the AB307-0294 BAP gene prior 
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Fig. 1 Organization of BAPs coding sequences in wholly sequenced A. baumannii genomes. The organization of coding sequences homologous 
to BAP [15] in wholly sequenced A. baumannii genomes deposited at the KEGG (Kyoto Encyclopedia of Genes and Genomes) site is depicted. 
Boxes denote NH2 and COOH regions, ovals modules of the repetitive region. Modules within small ORFs spanning the repetitive region in 
different clones have not been reported for clarity. Numbers in parenthesis denote ORFs, numbers to the right of each protein the strain ST 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   
   
   
 
 
 
 
 
 
 
 
 
to whole-sequencing, or denote sequencing errors. In 
this context, it may be worth noting that the Salmonella 
thyphimurium LT2 strain encodes a 386 kDa BAP, but 
the corresponding gene is annotated in GenBank as a 
pseudogene because of a frameshift mutation [26]. In 
other A. baumannii genomes, BAP homologous sequences 
are split in two or more ORFs (six in strains 1656–2, 
MDR-TJand ACICU). It is unlikely to hypothesize in all 
instances that the fragmentation reflects sequencing er- 
rors, sequencing data having been obtained by different in- 
vestigators. In several ST2 strains (ZW85-1, BJAB0714, 
BJAB0868, MDR-TJ, MDR-ZJ06), BAP prematurely termi- 
nates at residue 737. The corresponding COOH region, 
preceded by a variable number of repeats, is encoded by 
downstream flanking ORFs. This finding and the size 
identity of small BAP ORFs in MDR-TJ and ACICU 
strains, both support the notion that allelic BAP-negative 
variants, spread by horizontal gene transfer, may be com- 
mon in the bacterial population. In the ATCC17978 and 
A12 strains, the BAP gene was disrupted by a 7 Kb DNA 
insertion in TYTH-1, and by chromosomal rearrange- 
ments moving away, or flipping the NH2 and COOH re- 
gions. In six strains, either the NH2 or the COOH region 
is missing, in AC29 thetwo regions are at 2.7 Mb distance 
(Fig. 1). 
 
BAP in A.  baumannii draft  genomes 
Data in Fig. 1 suggest that BAP may be an accessory, 
dispensable gene expressed by subsets of the A. bau- 
mannii population only. To learn more, BAP homologs 
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were searched by tBLASTn in a large set of draft ge- 
nomes of A. baumannii. MLST analyses were performed 
at the A. baumannii MLST website (http://pubmlst.org/ 
abaumannii/) using the “Pasteur” MLST scheme [25]. 
Only strains which could be assigned to an ST were se- 
lected for further studies. The degree of identity of rpoB 
gene sequences helped to reassign several strains anno- 
tated as A. baumannii to other species. On the whole, 
the A. baumannii strains analyzed in this work (both 
complete and draft genomes) are 541 and belong to 108 
different STs (Additional file 1). For sake of simplicity, 
hereon draft genomes and/or the corresponding strains 
will be referred to by the four-letter code in the Gen- 
Bank accession number (see Additional file 1). 
Intact BAP coding sequences have been identified only 
in the AYOI (6207 aa) and JEVZ (6219 aa) strains. In a 
few high quality draft genomes (AFDB, AFDK, AYOH, 
JFEL, JFXM), BAP coding sequences resided in one con- 
tig, but were interrupted by stop codons, and split into 
two or multiple ORFs, as in many wholly sequenced 
genomes shown in Fig. 1. In the remaining WGS, se- 
quences encoding NH2 and COOH BAP regions, 
flanked by segments of the central repetitive region of 
variable lengths, were at the termini of two contigs. The 
stop codon at BAP residue 738 found in several wholly- 
sequenced genomes is a signature conserved in 42 % 
(118/282 genomes) of the ST2 strains analyzed. Given 
the prevalence of ST2 strains, interrupted BAP genes 
may be frequent in the A. baumannii population. 
The NH2 and COOH regions were conserved in most 
of the clones analyzed. Changes in the region encom- 
passing the terminal 397 aa mark BAP-2b and BAP-2c 
variants which exhibited 46 and 41 % identity to BAP-2 
in the diversity region, respectively. BAP-2b have been 
found in all the 12 ST499 strains analyzed and two ST2 
strains (AFTC and AMSX), BAP-2c in the single ST35 
APRA and the ST504 JEXU strains. 
Changes in the composition of the BAP repetitive re- 
gion were also observed. A novel Ig-like Z repeat unre- 
lated to A-D repeats was identified in 69 strains 
belonging to 26 different STs. As sketched in Fig. 2, the 
overall module organization in Z-positive and Z-negative 
regions differs. Type-3 BAPs have the same NH2 region 
of type-1 and type-2 BAPs, but differ both in the repeti- 
tive and the COOH regions. The repetitive region fea- 
tures D, Zb (a Z variant restricted to type-3 BAPs), W 
and Y modules (Fig. 2,; the sequence of the modules are 
in Additional file 2). The COOH region (1169 aa) of 
type-3 BAP exhibits only 40 % identity to the corre- 
sponding region of type-1 or type-2 BAPs. EFG modules 
are absent, but a tract of approximately 60 aa, exhibiting 
50 % identity to G repeats, could be identified. The 26 
clones carrying type-3 BAPs belong to 14 different STs, 
and about half of them belong to ST25. Type-3 BAPs 
 
 
 
are relatively limited in size, the largest complete protein 
found in the AFDL strain measuring 2700 aa (Additional 
file 2). Here too, however, it must be emphasized that 
the complexity of the repetitive region might have been 
missed in sequencing assembly. 
On the whole, strains encoding type-1, type-2 and 
type-3 BAP belong to 29, 40 and 11 % of the STs ana- 
lyzed. The remaining STs lack BAP, or carry truncated 
forms of the protein. 
 
BAP-like proteins encoded by the A. baumannii SDF strain 
The A. baumannii SDF strain, isolated from a human 
body lice [27] encodes two unusual BAP-like proteins, 
ABSDF785 (2321 aa) and ABSDF2314 (2402 aa), which 
exhibit significant homology to BAPs at the NH2 
terminus only. In both, Ig-like repeats are replaced by 
long stretches of alternating serine (S) and aspartic acid 
(D) residues (501 and 701 SD repeats in ABSDF785 and 
ABSDF2314, respectively). 
 
BAPs in  other  Acinetobacter  species 
BAP proteins occur in the genomes of several non-bau- 
mannii Acinetobacter strains (Additional file 3). The list 
includes the A. baylyi ADP1, all the strains classified as 
A. calcoaceticus (taxid 471), A. pittii (taxid 48296), and 
A. radioresistens (taxid 40216), as several A. haemolyti- 
cus (taxid 29430) and A. nosocomialis (taxid 106654) 
strains, only one (APPX) of the six strains classified as 
A. junii (taxid 40215) BAP proteins are missing in A. 
johnsonii and A. lwoffii. 
A B A 
C Z B C 
W 
W W Zb 
A   B   C A   B C C D 
n n n 
 
A   B   C    
1-3 
A   B   C   C Z C Z C 
1-3 2-4 
type-1 and type- 2 BAP 
W   W   W D D W Zb  Y   Zb 
3 
AFDL 
D D W Zb   Y Zb AEPM 
Zb  Y AFDA 
type-3 BAP 
Fig. 2 Repeat modules in type-1, type-2 and type-3 BAPs. Bars 
denote undefined repeat regions in Z-plus type-1 and type-2 BAPs. 
AFDL, AEPM and AFDA clones potentially express a complete 
type-3 BAP 
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Acinetobacter BAPs have been classified as alpha or beta 
forthepresence of either Ig-likeor SDrepeats as repetitive 
modules, respectively, and assigned to 8 types on the basis 
of their COOH regions (Fig. 3). In addition to A. bauman- 
nii, type-1 andtype-2 BAPs have been found in A. calcoa- 
ceticus, A. pittii and A. nosocomialis, while type-3 BAPs 
are confined to A. baumannii. A. baylyi and A. radioresis- 
tens BAP-like proteins markedly differ from A. baumannii 
BAPs because the repetitive region features either 
highly divergent copies of a single Ig-like module 
(type-4), or novel Ig-like modules interrupted by for- 
eign aa stretches (type-5) (Additional file 4). 
Type-6 and type-7 beta-BAPs differ for the presence/ 
absence of B modules in the repeat region. Curiously, A. 
pittii and A. calcoaceticus strains producing beta-BAPs 
potentially encode also alpha type-1 BAPs. A. haemolyti- 
cus type-8 BAPs are hybrid alpha/beta proteins which 
resemble type-1 BAPs in the COOH region, but feature 
long tracts of alternating aa in the repetitive region. The 
complete proteins encoded by the A. haemolyticus 
ATCC19194 and TG19602 strains feature 79 SD pairs 
and 148 AD pairs, respectively. 
The NH2 region is largely conserved in all BAPs, but 
three main variants, denoted by the color code in Fig. 3, 
could be recognized (Additional file 5). Curiously, the A. 
baumannii and A. haemolyticus NH2 regions both fea- 
ture a 38 aa insertion mostly made by tandem DA re- 
peats. Significant similarities of the COOH regions of 
the various BAP types are limited to the terminal 100– 
150 aa. It may be worth noting that only G modules are 
conserved inmany BAPs (Additional file 5). 
The analysis ofwholly sequenced genomes showed that 
alpha- and beta-BAP genes map at different chromosomal 
sites. The alpha gene region is conserved in A. baumannii, 
A. calcoaceticus PHE-A2 and A. baylyi ADP1 genomes. In 
the A. baumannnii SDF strain, the region is also con- 
served, but is occupied by the beta-BAP ABSDF785 gene. 
The beta gene region is located on genomic islands, 
flanked by lapEBC genes coding for components of a 
type-I secretion system, both in A. calcoaceticus PHEA-2 
and A. baumannii SDF strains (Additional file 6). SD-rich 
adhesion protein genes flanked by lap genes have been 
found in different Gram-negative microrganisms, such as 
Klebsiella pneumoniae MGH 78578 (ORF KPN_00994), 
and Enterobacter aerogenes EA1509E (ORF ST548_p6177). 
 
Additional proteins with Ig-fold motifs encoded by A. 
baumannii 
In A. baumannii, two additional proteins were found to 
contain Ig-like repeats. The proteins, variously named in 
 
 
 
NH 
2 
repeats COOH 
Acinetobacter species 
type-1 A,B,C,D,Z Bau, Cal2, Pit, Nos 
type-2 A,B,C,D,Z Bau, Cal2, Pit, Nos 
α type-3 W,D,Z,Y Bau 
type-4 H Bay 
type-5 B,C,M,N Rad 
type-6 (Asp Ser) n Cal1, SDF, Pit 
β type-7 (Asp Ser) n Cal2 
type-8 
(Asp Ser) 
or 
n Hae 
(Asp Ala) 
n 
 
Fig. 3 Alpha and beta BAPs. Changes in the organization of the 8 BAP types found in the Acinetobacter genus are highlighted. Bau, A. baumannnii; 
SDF, A. baumannnii SDF; Hae, A. haemolyticus; Pit, A. pittii; Nos, A. nosocomialis; Bay, A. baylyi, Rad, A. radioresistens, Cal, A. calcoaceticus. Cal1 and Cal2 
refer to the wholly sequenced A. calcoaceticus PHE-A2 [41] strain and the draft genomes deposited at the NCBI, respectively. Sequences conserved at 
the end of all BAP types are in orange. For sake of simplicity difference in the COOH regions among BAPs are not highlighted. E, G, F and B modules 
are depicted as in Fig. 1 
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different annotations, have been named, for sake of sim- 
plicity, BLP1 and BLP2. Both BLPs and BAP share a se- 
quence motif at the NH2 terminus. BLP1 and BAP 
feature COOH-terminus aa sequences similar to those 
found in RTX toxins, proteins secreted through a type I 
secretion system ([28]; see Fig. 4). In the AYE strain, 
BLP1 and BLP2 correspond to ORFs 821 and 1037, re- 
spectively, and BAP to ORF 792. BAP and BLP1 genes 
are thus very close (approximately 30 kb away), and their 
relative position is conserved in all strains examined. 
BLP1 and BLP2 exhibit the same tripartite structure of 
BAP (Fig. 5). In BLP1, the repetitive region is made up 
by four different repeat types (P, Q, R, S), all but Q fea- 
turing Big_3_4 motifs (Additional file 7). BLP1 vary in 
length from 3044 to 3356 aa. BLP1 has a small number 
of repeats, and complete proteins have been identified in 
about 60 % of the examined WGS. Aminoacids changes 
let to distinguish type-1 and type-2 BLP1 variants, exhi- 
biting 86 % identity in a 552 aa domain of the COOH 
region. The nomenclature reflects the occurrence of 
type-1 and type-2 BLP1 in clones of the predominant 
ST1 and ST2 types. Type-2 variants featuring a more 
extensive remodeling of the variable domain are 
encoded by a few strains, each belonging to a differ- 
ent ST, and have been named H and K variants (see 
Additional file 7). 
BLP2 features a simple repetitive region made by only 
four T repeats, and a relatively small (207 aa) COOH re- 
gion. The protein is conserved in most of the strains ex- 
amined, and four main sequence variants (A-D) could 
be recognized. The A-type has been found in >70 %(77/ 
108) of the STs examined, including the predominant 
ST1 and ST2. The minor B, C and D variants, which ex- 
hibit decreasing similarity to the A-type protein, have 
been found in 11, 13 and just 2 STs,respectively. Inboth 
C- and D-type proteins, the Ig-like domain of one T re- 
peat is mutated (Additional file 7). 
In contrast to BLP2, BLP1 had been identified only in 
80 % of the clones analyzed. BLP1-negative strains fall 
into two distinct groups. In the JFXH, APWV and ATGJ 
strains, the BLP1 coding region had been completely or 
partly deleted. In the majority of BLP1-negative strains, 
however, the BLP1 coding region is invariably replaced 
by a 99 bp DNA tract (Additional file 8). 
 
BLPs  in  other  Acinetobacter  species 
BLP1 and BLP2 genes were searched in non-baumannii 
Acinetobacter genomes (Additional file 3). A. calcoaceti- 
cus and A. pittii strains encode both BLPs, A. haemolyti- 
cus and A. nosocomialis strains BLP2 only. In all the 
BLP1-negative species, sequences homologous to the 
99 bp DNA tract found in the A. baumannii BLP1- 
negative clones could be identified (Additional file 8). 
The presence/absence of BLP1 in the A. baumannii 
population can thus be rationalized by hypothesizing 
that the BLP1 gene region had been replaced by the cor- 
responding “empty site” upon recombination with non- 
baumannii cells. Exchange of the BLP1 locus among 
Acinetobacter cells is frequent, as indicated by the spread 
in A. baumannnii of the H and K BLP1 variants found 
in A. calcoaceticus and A. pittii strains. 
A. johnsonii, A. lwoffii and A. junii strains lack both 
BLP1 and BLP2. In 5/6 A. junii genomes analyzed, 
BLP2-like genes are inactivated by a frameshift mutation, 
separating NH2 and COOH regions into two ORFs, and 
the BAP gene is missing. Only the A. junii APPW strain 
encodes an intact BLP2, and is worth noting that only 
this strain potentially encodes also a BAP protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 Conserved motifs in BAP, BLP1 and BLP2. Sequence motifs conserved at the termini of the three proteins are highlighted. RTX refers to the 
1450 aa RTX toxin (ORF1891) encoded by the A. baumannii ACICU strain 
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Fig. 5 A. baumannii BLP1 and BLP2 proteins. The modular organization of the two proteins is diagrammed. The 297 aa “unique region” between 
P and Q repeats in BLP1 is depicted by a bar 
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Sequence type distribution of BAP, BLP1 and BLP2 
The distribution of BAP, BLP1 and BLP2 among ana- 
lyzed STs is summarized in Additional file 9. A close 
look at data support the notion that the three proteins 
may be functionally related. BLP1 seems ancillary to 
BAP, since it is missing in almost all the STs (14/16) 
which lack BAP. Among BAP-positive strains, the BLP1 
gene is unevenly distributed. BLP1 was found in most 
(42/47) STs expressing a type-2 BAP, 60 % of STs ex- 
pressing a type-1 BAP, only in one of the 12 STs express- 
ing a type-3 BAP. Moreover, type-2 BAP and type-2 
BLP1 are more frequently associated than type-1 BAP 
and type-1 BLP1. Thus, the coexistence of some BLP1 
and BAP variants may be preferred, while specific com- 
binations may plausibly be disadvantageous, and this 
may explain the exchange of filled/empty BLP1 sites ob- 
served in the population. BLP2 is conserved in most of 
the clones examined. Several BAP-negative STs lack 
BLP2, others feature BLP2 variants which may be func- 
tional impaired because carrying mutations in one Ig- 
like domain (Additional file 9), suggesting that BAP and 
BLP2 may be interdependent. The hypothesis that BAP 
and BLP2 may functionally interact was reinforced by 
the analysis of A. junii genomes. BAP and BLP2 are ab- 
sent in all A. junii strains examined but the APPW 
strain, in which both proteins are present. 
Functional link of BAP, BLP1 and BLP2 was further 
provided by the results of quantitative RT-PCR analyses 
in which the levels of the corresponding transcripts were 
monitored. For all, RNA levels were undetectable in log- 
phase, high in late stationary phase (data not shown). 
 
Biofilm  formation  in  different  A.  baumannii  strains 
We thought of interest to evaluate differences in the 
type and extent of biofilmformation among A. bauman- 
nii strains belonging to different STs, and presenting a 
different combination of BAP and BLP1 proteins by 
CLSM (Confocal Laser Scanning Microscopy) analyses. 
The ACICU (type-2 BAP, BLP1-plus) and the 4190 
(type-3 BAP, BLP1-negative) strains, assigned to inter- 
national clone II and ST25 epidemic clonal lineage, 
respectively, were shown to be relatively strong biofilm 
producers [4]. Both strains carry pga, csu and ompA 
genes shown to be involved in biofilm production. Bio- 
films formed by the two strains have comparable 
heights, but different architectures (Fig. 6, panels a and 
b). The ACICU biofilm exhibited a total substratum 
coverage. By contrast, the 4190 biofilm was made up by 
large, evenly distributed microcolonies, separated by 
water channels. The ATCC17978 strain also carries pga, 
csu and ompA genes, but lacks both BLP1 and BAP1. 
Yet, this strain formed a dense biofilm, exhibiting an 
uniformely surface coverage. However, microcolonies 
were undetectable (Fig. 6, panel c). The heterogeneity of 
the biofilms formed by the analyzed strains is not sur- 
prising. The plethora of genes shown or hypothesized 
[11] to be involved in biofilm formation in A. baumannii 
makes difficult evaluating the role that different BAP 
types, and the presence/absence of BLP1, may play in 
the process. We thought therefore to address the prob- 
lem by mutating, as done for the BAP gene in the B307- 
0294 strain [15], the BLP1 and BLP2 genes of the AYE 
strain. Either gene was inactivated by allelic replacement 
[29]. The test strain encodes a sequence-proved intact 
BAP, comparable in length and composition to the 
B307-0294 protein (see Fig. 1). BAP and BLP1 expressed 
by the AYE and B307-0294 strains, which both belong to 
sequence type 1, are functionally comparable, because 
unaffected by size changes which may influence their ex- 
posure on cell surface, as proved for repetitive S. aureus 
SDR proteins of different lengths [30]. The biofilms 
formed on glass by AYE and its BLP1 deletion derivative 
AYE-Δblp1 markedly differed. AYEformed a typical bio- 
film structure (Fig. 7a), in which distinct microcolonies 
could be distinguished. In contrast, AYE-Δblp1 formed 
just a thin monolayer. The width of the bioflm formed 
by AYE averaged 22 microns. The biofilm formed by the 
mutant (average 4 microns) was barely measurable 
(Fig. 7b). Inactivation of BLP2 also affected biofilm for- 
mation (Fig. 7c). The AYE-Δblp2 mutant produced a 
biofilm only twice thinner than AYE. However, in con- 
trast to the AYE-Δblp1 biofilm, the coverage was 
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reduced, and microcolonies could not be detected. 
Quantitative estimates obtained using the IMARIS v7.0 
software (Bitplane, Switzerland) allowed measuring the 
total biomass of biofilms as micrometers
3 
[31]. Quantita- 
tive estimates of the biofilms formed by AYE, AYE- 
Δblp1 and AYE-Δblp2 are shown in Fig. 8. A significant 
correlation was found between biofilm biomass and bio- 
film thickness of AYE and AYE-Δblp1 and AYE-Δblp2 
mutant strains (r = 0.9974, p = 0.0455). 
 
Adherence of A. baumannii wild type AYE and AYE-Δblp1 
and AYE-Δblp2 mutant strains to A549 human bronchial 
cells 
We next investigated the ability of AYE, AYE-Δblp1 
and AYE-Δblp2 strains to adhere to A549 human 
alveolar epithelialcells. As shown in Fig. 9, AYE showed 
a statistically significant higher adherence to A549 hu- 
man bronchial cells compared with AYE-Δblp1 and 
AYE-Δblp2 mutant strains, which showed a reduction 
in adherence by 2.9- and 1.7 fold, respectively. More- 
over, significant correlations were found between adhe- 
siveness to epithelial cells and biofilm biomass (r = 
0.9999, p = 0.0104) and bacterial adhesiveness to epithe- 
lial cells and biofilm thickness (r = 0.9985, p = 0.0351) 
for AYE, as for AYE-Δblp1 and AYE-Δblp2 mutants. 
On the other hand, AYE and mutant strains were not 
able to invade A549 cells human alveolar cells (data not 
shown). Also, a similar number of bacteria adhered to 
A549 cells when the monolayers were incubated with 
A. baumannii strains for 60 min at 4 °C, i.e. under 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 CLSM analysis of biofilms formed by the A. baumannii strains ACICU (a), 4190 (b), and ATCC17978 (c). In each panel, to the left is shown 
the orthogonal view of Z-stacks, to the right the three-dimensional spatial distribution of the biofilm. Arrows denote biofilm heights. Bright and 
dark areas show cell clusters and voids in the biofilm 
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conditions that do not allow for tissue invasion (data 
not shown). 
 
Variable  assortment  of  other  surface  proteins 
We checked next whether the distribution of other sur- 
face proteins may similarly vary among A. baumannii 
strains. OmpA, the abundant 356 aa protein involved in 
biofilm formation [13] is highly conserved (>95 % iden- 
tity) in most isolates. In 16 clones, however, a protein 
variant exhibiting only 70 % identity at the NH2 side 
(residues 35–183 aa) was detected (Additional file 10). 
Interestingly, all these clones but one potentially 
expressed a type-3 BAP. SURP-1 (SUrface repetitive pro- 
tein 1) is a 904 aa protein with a central region made by 
84–93 aa repeats (Additional file 10) unrelated to either 
BAP or BLP1. SURP-1 has been found only in 65 % of 
the ST. The protein is missing in all STs featuring type-3 
BAP, except ST 215, 50 % of BAP-negative STs, most of 
the BAP-plus/BLP1-negative STs. The distribution of 
OmpA and SURP-1 among the various STs is summa- 
rized in Additional file 9. 
 
Discussion 
Most bacterial species form biofilms, and the identifica- 
tion of the genetic determinants controlling this com- 
plex process became an active field of research in recent 
years, given the implications that biofilm formation has 
in medical care. As in other pathogens, a large protein 
expressed at the A. baumannii cell surface, known as 
biofilm-associated protein or BAP, has a role in biofilm 
formation as in host cell adherence [15, 17]. Compara- 
tive genome analyses carried out over hundreds of 
Fig. 7 Biofilms CLSM analysis. Biofilms formed by the AYE (a), the AYE-ΔBLP1 (b) and AYE-ΔBLP2 (c) strains. Orthogonal view of Z-stacks, 
three-dimensional spatial distribution of the biofilm and arrows are as in Fig. 6 
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sequenced strains revealed that the A. baumannii BAP is 
highly polymorphic. The central repetitive region has a 
variegated structure, and type and number of repeat 
modules both vary among isolates. This region connects 
a relatively small NH2 domain, conserved in all BAPs 
which is plausibly exposed on the cell surface and in- 
volved in binding, to large COOH regions in turn host- 
ing a few, additional repeats. BAP COOH regions also 
vary, and three main types of proteins could be distin- 
guished. Type 1 and type 2 proteins are expressed by 
strains of the predominant clonal complexes 1 and 2 
strains, respectively, and have been identified also in A. 
calcoaceticus, A. pittii and A. nosocomialis, which form 
with A. baumannii the monophyletic ACB complex [32, 
33]. Type 3 BAPs feature short repetitive regions, which 
include novel repeat modules, and a COOH region exhi- 
biting only 40 % similarity to the corresponding regions 
of either type-1 or type-2 BAPs. This protein variant 
seems restricted to A. baumannii. However, taking into 
the account that the variant had been identified only in 
13/108 STs, and a relatively small number of non-bau- 
mannii Acinetobacter strains had been sequenced, it 
cannot be ruled out that type 3 BAP may be expressed 
also by other species of the ACB complex. 
The genus Acinetobacter hosts a variety of BAP pro- 
teins, all featuring large central repetitive regions made 
either by 80–100 aa long Ig-like repeats (alpha-type 
BAP), or homopolymeric stretches of alternating serine 
and aspartic acid, or serine and alanine residue contain- 
ing up to 500 dipeptides (beta-type BAP). Repetitive re- 
gions in both alpha- and beta-type BAPs span the cell- 
   wall allowing exposure of the N-terminal region to the 
environment [15, 30, 34]. The length of the repeat region 
has been shown to influence exposure of the S. aureus 
SDR proteins on cell surface [30], and the same may 
plausibly hold true for alpha-BAPs. In alpha-like BAPs 
found in other species, the repeat region originated by 
the expansion of a single module ([35, 36]). The rule is 
subverted in A. baumannii BAPs, which feature multiple 
repeats varying in length, composition and relative ar- 
rangement. A variegated repetitive region may be benefi- 
cial for such a large protein, which is a gain of specific 
isolates in many species, because encoded by mobile 
DNA, but is in contrast a conserved gene product in A. 
Fig. 9 Bacterial adherence of A. baumannii AYE, AYE-ΔBLP1 and 
AYE-ΔBLP2 strains to A549 bronchial epithelial cells. Cell 
surface-associated bacteria after 60 min incubation at 37 °C. Asterisks 
denote statistically significant (p <0.001) differences in the degree of 
cell adhesion of AYE and derivative clones 
baumannii. Modules diversification should decrease 
the chance that the protein may vary in size because of 
strand slippage during DNA replication. Moreover, a 
low sequence identity between modules strongly inhibits 
   misfolding and aggregation of repetitive proteins, and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8 Quantitative analysis of biofilm formation. The thickness (white bars) and the biomass (grey bars) of biofilms formed by the A. baumannii 
AYE, AYE-ΔBLP1 and AYE-ΔBLP2 strains are shown 
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consecutive homologous domains in large multi-domain 
proteins almost exclusively show sequence identities of 
less than 40 % [37]. 
As shown in this report, differences in size and extent 
of module variation among A. baumannnii BAPs both 
remain largely unknown. The number of isolates in 
which the BAP gene is functional, or had been inacti- 
vated by mutations within the repetitive region, as re- 
ported for different genomes (see Fig. 1), remains also to 
be established, and the issue may be settled for individ- 
ual strains only by expression analyses. Mapping repeti- 
tive DNA regions is a major bias in whole sequencing 
projects. Reconstructing the organization of the baroque 
BAP repetitive region is a tremendous, pitfall-rich task, 
and most of the sequence data on A. baumannnii BAP 
could be wrong, and need to be amended. Translation 
of the BAP gene RNA is interrupted at residue 737 of 
the protein in a high number of ST2 clones, but a −1 
frameshifting could let translation extending into down- 
stream BAP coding sequences. While the occurrence of 
both short and long BAP isoforms in these clones may 
be experimentally tested, data denote variation in the 
state of the BAP gene among strains of the same ST. In 
many isolates, the BAP is truncated, or absent. 
Altogether, the fraction of BAP-negative isolates belong- 
ing to different STs is elevated (Additional file 9). Thus, 
the BAP gene may be catalogued as a variable dispens- 
able gene. 
In A. baumannii, two additional proteins, BLP1 and 
BLP2, includea central repetitive region made by Ig-like 
repeats. BAP, BLP1 and BLP2 share a large sequence 
motif at the NH2 terminus, are co-expressed at the end 
of the stationary growth phase, and may work in con- 
junction. BLP1 is a large (3044 up to 3356 aa) protein 
which features a composite repetitive region, and can be 
typed, as BAP, into main sequence variants according to 
aa changes in the COOH region. BLP1 has been found 
in A. baumannii, A. calcoaceticus and A. pittii. In several 
A. baumannii isolates, the BLP1 coding region is miss- 
ing, and is invariably replaced by the same piece of DNA 
which is highly homologous to DNA tracts found, at the 
same relative chromosome position, in A. nosocomialis 
and other Acinetobacter BLP1-negative species. The co- 
existence of empty and filled BLP1 sites in the popula- 
tion implies recombination of A. baumannii with non- 
baumannii Acinetobacter cells. The genetic exchange 
plausibly occurred once, and the empty site status had 
been eventually maintained, probably because the ab- 
sence of BLP1 turned out to be advantageous in specific 
genetic milieu. The hypothesis stems from the uneven 
distribution of BLP1, conserved in most isolates express- 
ing type-2 BAP, but only in half of those expressing 
type-1 BAP, missing in isolates expressing type-3 BAP. 
BLP1 is also missing in most BAP-negative isolates. 
Altogether, data suggest that BAP and BLP1 may be 
interdependent. The proteins may interact and/or share 
a partner on the cell surface, and the combination of 
BLP1 with different BAP types may be beneficial or 
harmful. BLP2 is a smaller (728 aa) protein with a repeti- 
tive region made by only 4 Ig-like repeats. The protein, 
found in all the species of the ACB complex, is highly 
conserved in A. baumannii. BLP2 may also be a compo- 
nent of surface protein complexes involved in biofilm 
formation. The conclusion stems from the observation 
that BAP-negative strains belonging to different STs lack 
BLP2, or feature BLP2 with mutated Ig-like domains. 
Moreover, BAP and BLP2 are both absent or present in 
all A. junii strains examined. 
A link between BAP and BLPs is suggested by the ob- 
servation that gene disruption of either BLP gene im- 
paired biofilm formation, as proved by SCLM analyses 
(Figs. 7 and 8). Similarly to BAP, the BLP1- and BLP2- 
negative derivatives AYE-Δblp1 and AYE-Δblp2 also 
showed a reduced adherence to human epithelial cells 
(Fig. 9). Other surface proteins, known or hypothesized 
to be involved in biofilm formation, may interact and/or 
be assembled with BAP and BLPs on the cell surface. 
OmpA has a role in biofilm formation [13] and is highly 
conserved in the A. baumannii population. Interestingly, 
the protein varies significantly in sequence composition 
in most clones expressing type-3 BAP. SURP-1, a repeti- 
tive protein structurally related to BAP and BLPs, is 
missing in most type-3 BAP, as in many BLP1-negative 
clones. The uneven distribution of the various BAP 
types, OmpA variants, BLP1 and SURP-1 proteins 
among isolates is indicative of alternative combinations 
of surface proteins in the A. baumannii population. 
Consequently, the architecture of the biofilm formed by 
different isolates may greatly vary. 
Conclusions 
The construction of clones expressing BAP and BLPs 
isoforms in all possible combinations is important to 
clarify the role played by each protein in biofilm forma- 
tion of A. baumannii, establish whether the proteins 
interact, assess underneath hierarchies. In parallel, mu- 
tational analyses may shed light on the functional 
organization of therepetitive regions of BAPs and BLPs, 
and establish how the combination of specific modules 
may influence secretion and surface exposure of each 
protein. 
The assay of type-3 BAP derivatives may be crucial to 
assess whether the unicity of this protein, which seems 
mutually exclusive relative to other surface components, 
correlates with the particular combination of Ig-like 
modules in the repetitive region and/or their paucity, or 
resides inthe COOH region. 
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Methods 
In silico data 
Tblastn searches of BAP and BAP-like proteins in A. 
baumannii and other Acinetobacter species WGS were 
carried at the National Center for Biotechnology Infor- 
mation (NCBI) (http://www.ncbi.nlm.nih.gov/). Modules 
in BAP repetitive regions were marked according to the 
AB307-0294 BAP protein nomenclature ([15]; accession 
number EU117203). 
Tandem repeats in BAP, BAP-like and other repetitive 
proteins were identified by using the XSTREAM (vari- 
able Sequence Tandem Repeats Extraction and Architec- 
ture Modeling, [38]) and the RADAR (Rapid Automatic 
Detection and Alignment of Repeats, [39]) algorithms. 
Searches are restricted to Whole Genome Shotgun 
(WGS) genomes deposited at GenBank before March 
2014. 
Construction of AYE-Δblp1 and AYE-Δblp2 mutants 
The genes encoding the BLP1 and BLP2 proteins of the 
A. baumannii AYE strain [27] were mutagenized by al- 
lelic replacement, according to the published procedure 
[29]. Flanking fragments located immediately upstream 
and downstream from the AYE A. baumannii BLP1 and 
BLP2 genes were amplified by PCR and cloned into the 
suicide vector pMo130-TelR, which contains the 
tellurite-resistance marker and the sacBR genes con- 
ferring sucrose sensitivity [29]. Upstream and down- 
stream BLP1 and BLP2 fragments were amplified 
using the pairs of BLP1 and BLP2 up and dw primers 
shown below: 
BLP1up-fw: tatgcggccgcaacagcctgaagtgattgttgtg (NotI 
site underlined) 
BLP1up-rv:  gctggatccttaatatcaatttttgcgattaccttc  (BamHI 
site underlined) 
BLP1dw-fw: tatggatcctagacgaattactaaacaaccagca 
(BamHI site underlined) 
BLP1dw-rv: tatgcatgcatcagctggtttagcaatagaacg (SphI site 
underlined) 
BLP2up-fw: tatgcggccgcaaaggtgacattcaggcatc (NotI site 
underlined) 
BLP2up-rv: gctggatccatcttgcagaacgtccaaac (BamHI site 
underlined) 
BLP2dw-fw: tatggatcctccagttgtttagggtatttgag (BamHI 
site underlined) 
BLP2dw-rv: tatgcatgctattggtaaacttgaactcaatgc (SphI site 
underlined) 
PCR products were digested with NotI-BamHI (up- 
stream fragments) and BamHI–SphI (downstream 
fragments), and cloned into NotI-SphI restricted 
pMo130-TelR DNA, to create pMo130-TelR-ΔBPL1 
and pMo130-TelR-ΔBPL2, respectively. 
Each pMo130-TelR derivative was introduced into E. 
coli S17-1 by transformation, and subsequently mobi- 
lized to the A. baumannii AYE strain via conjugation as 
described [29]. pMo130-TelR derivatives integrated into 
the AYE genome by homologous recombination (first 
crossovers) were selected on LB agar containing 30 μg/ 
ml tellurite and 50 μg/ml ampicillin. Transconjugants 
were cultured in LB broth containing 10 % sucrose to 
select double recombinants, and serial dilutions were 
spread onto LB plates containing 10 % sucrose. Sucrose- 
resistant colonies were screened for tellurite sensitivity 
to monitor excision of the suicide vector. The inactiva- 
tion of BLP1 and BLP2 genes in tellurite sensitive col- 
onies was confirmed by PCR amplification, using the 
primers that annealed to DNA immediately flanking the 
deleted BLP1 and BLP2 gene regions shown below: 
BLP1mut-fw:tgtagtagatccgaaggtaatcg 
BLP1mut-rv: ccagataggtacagaagatgaagc 
BLP2mut-fw: tttggacgttctgcaagatg 
BLP2mut-rv:  aattggcgcaatcctctatg 
Control PCR assays were performed to rule out that 
merodiploids containing both the intact and the deleted 
gene had been selected, using the “wild-type” primers 
listed below: 
BLP1wt-fw:    cgaaggtaatcgcaaaaattg 
BLP1wt-rv:    atgtaatggacgaatgttgctc 
BLP2wt-fw:   ccagatgttccacaagctca 
BLP2wt-rv:    ccgcttcactggttaatggt 
Biofilm assay 
Experiments were carried out in TSB (Tryptic soy broth; 
[31]). Overnight bacterial cultures were diluted with TSB 
to concentration of 10
8 
CFU/ml. Approximately 2×10
5
bacteria was added to cell culture plates containing glass 
coverslips and incubated in static conditions at 37 °C for 
48 h. The coverslips were then washed 3 times with PBS 
to remove non-adherent bacteria. Biofilms were stained 
with LIVE/DEAD
® 
BacLight
™ 
Bacterial Viability kit for
microscopy (Molecular Probes) as described prior [40]. 
The images were captured using LSM 710 inverted con- 
focal laser-scanning microscope (Zeiss). Quantitation of 
mean biomass was determined using the IMARIS v7.0 
software package [31]. Each experiment was performed 
in triplicate. 
Cell adhesion assays 
Adherence of A. baumannii strains to A549 cells (human 
type 2 pneumocytes) was determined as described previ- 
ously [4], with minor modifications. In brief, ~ 10
5 
A549
cells were infected with ~ 10
7 
bacterial CFU and incubated
for 60 min at 37 °C in 5 % CO2 (v/v) atmosphere. Non- 
58 
adherent bacterial cells were removed by washing with 
PBS. Infected cells were lysed by the addition of 1 ml dis- 
tilled water and serial 10-fold dilutions were plated on LB 
agar to determine the number of CFU of adherent bac- 
teria. To determine adherent and invading bacteria, A549 
cells were infected with A. baumannii strains as described 
above. The monolayers were then treated with 1 ml of 
fresh culture medium containing 5 mg/L of colistin sulfate 
(Sigma-Aldrich,Milan,Italy) forfurther 30 min,the short- 
est time point that resulted in the killing of all extracellu- 
lar bacteria added to the monolayers. Afterwards, the cells 
were washed with PBS, harvested with trypsin, and lysed 
with sterile distilled water. Dilutions from harvested sam- 
ples were inoculated on LB agar plates and bacterial col- 
ony counts were estimated after overnight incubation at 
37 °C. Each experiment was performed in triplicate. 
Statistical analysis 
Data were analysed using Statistical Package for the 
Social Sciences Version 13.0 (SPSS Inc., Chicago, IL, 
USA). Differences between mean values were tested for 
significance by performing either unpaired, two-tailed 
Student’s t-tests or one-way ANOVA analysis followed 
by Tukey’s multiple-comparison test, when appropriate. 
A P value <0.05 was considered to be statistically signifi- 
cant. Correlations were evaluated by regression analysis 
using the Pearson’s correlation coefficient (r). 
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Concluding remarks 
A. baumannii is a globally important nosocomial pathogen responsible for widespread and 
persistent outbreaks among hospitalized patients. A. baumannii had a clonal population 
structure dominated by three international clonal lineages I–III and a few additional 
epidemic lineages, including emerging genotype ST25. A. baumannii epidemic clonal 
lineages were selected because of extensive antibiotic resistence, in particular the 
majority of epidemic A. baumanni isolates (>90%) are carbapenem-resistant and express 
OXA-23 carbapenem-hydrolyzing class D (CHDL) oxacillinase. This extremely rapid 
development of antimicrobial resistance is due to the widespread use of antimicrobials in the 
hospital environment and to the ability of A. baumannii to respond rapidly to challenges 
issued by antimicrobials. The widespread administration of polymyxin antibiotics such as 
colistin in the hospital setting has exerted selective pressure for the development of resistance 
in A. baumannii clinical isolates. Colistin-resistant (colistin-R) A. baumannii strains showed 
activating mutations in the PmrB sensor kinase of PmrAB 2-component system. In addition 
to In addition to extensive antimicrobial resistance, A. baumannii strains responsible for 
epidemics show elevated resistance to desiccation, high biofilm-forming capacity on abiotic 
surfaces and adherence to host epithelial cells, virulence-related features which might have 
favored the spread and persistence in the hospital environment. Biofilm-forming capacity on 
abiotic surfaces and adherence to host epithelial cells is dependent on the expression of 
biofilm associated proteins BAB, BLP1 and BLP2. 
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